,,,,,Paper Information,,,,,,,,Population Information,,,,,,,,,,,,,Demographic Characteristics,,,,,,,Exposure history,,,,,,,,,,,Comorbidities,,,,,,,,,,,,Symptoms,,,,,,,,,,,,,,,,,,,,,,,Labs,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Treatments,,,,,,,,,,,,,,,,,,Medical Outcomes,,,,,,,,,,,,,,Outcomes,,,,,,,,Outcomes (Imaging),,
ID,SUB_ID,Country,Province/State,Pop Size (N),Title,Journal,Author,Source,Language,Notes,Person Responsible,Data Request (contact person),Study start date (mm/dd/yyyy),Study end date (mm/dd/yyyy),Study length (days),Is top-level row?,Subgroup,Positive/negative cases,End-point vs Active,Survivors,Discharged,Contains Any Treatment?,ICU vs. non-ICU,Severity,Ventilation,Median Age,Mean Age,Age 95% CI Halfwidth,Age Lower Quartile,Age Higher Quartile,% Healthcare Worker,% Male,Exposure history (%),Exposure - Wuhan Travel (%),Exposure - Personal Contact (%),Incubation period (days) - Mean,Incubation period (days) - Median,Incubation period (days) - Lower Quartile,Incubation period (days) -  Higher Quartile,Time From Ill (days) - Mean,Time From Ill (days) - Median,Time from Ill (days) - Lower Quartile,Time from Ill (days) - Upper Quartile,Current smoker,Current drinker,Any Comorbidity,Hypertension,Diabetes,Coronary heart disease,Cardiovascular Disease,Chronic obstructive lung,Cancer (Any),Carcinoma,Chronic kidney/renal disease,Other,Respiratory rate > 24 breaths per min,Pulse >=125 beats per min,Systolic blood pressure <90mm Hg,Fever (temperature ≥37·3°C),Average temperature (celsius),Max temperature (celsius),Cough,Shortness of Breath (dyspnoea),Headache,Sputum (/Expectoration),Myalgia (Muscle Pain),Fatigue,Upper air-way congestion,Diarrhoea,Nausea or vomiting,Loss of Appetite,Sore Throat/Stuffy Nose,Chills,Chest Pain,Disease Severity Asymptomatic,Disease Severity General,Disease Severity Severe,Disease Severity Critical,Peripheral white cell count - Median,Peripheral white cell count - Lower Quartile,Peripheral white cell count - Upper Quartile,Hemoglobin (g/L) - Median,Hemoglobin (g/L) - SD,Hemoglobin (g/L) - Lower Quartile,Hemoglobin (g/L) - Upper Quartile,"Imaging Findings Available? (yes=1, no=0)",Hematocrit,CRE (μmol/L),Lymphocyte count - Median,Lymphocyte count - Lower Quartile,Lymphocyte count - Upper Quartile,Platelet count - Median,Platelet Count - SD,Platelet count - Lower Quartile,Platelet count - Upper Quartile,Serum bilirubin - Median,Serum bilirubin - Lower quartile,Serum bilirubin - Upper quartile,Neutrophils,ALT (U/L),AST (U/L),GGT (U/L),CRP (mg/DL),IL-6 (ng/L),D-Dimer (mg/L),Albumin (g/L),Creatinine (umol/L),BUN (mmol/L),Creatine Kinase (U/L),"PCT (Procalcitonin), ng/mL",CD4+ T Lymphocyte (Count),CD8+ T Lymphocyte (Count),Lymphocyte count <0.8 * 10^9/L,CRP ≥ 10 mg/liter,AST >40 U/l,ALT >40 U/l,Total Bilirubin >20.0 umol/L,Creatinine ≥ 84.0 umol/L,Antibiotic,Antiviral,Uses Kaletra (lop-rit),Uses Favipiravir,Uses umif+lop-rit,Uses umifenovir,Uses hydroxychloroquine and/or chloroquine,Corticosteroid,Intravenous immunoglobin,Nasal cannula,High-flow nasal cannula oxygen therapy,Noninvasive mechanical ventilation,Invasive mechanical ventilation,ECMO,Glucocorticoid,Renal replacement therapy,Interferon Alpha-1b,Thymalfasin,Sepsis,Respiratory failure or ARDS,Respiratory failure,ARDS,Hypoxemia,Heart failure,Septic shock,Liver dysfunction,Coagulopathy,Acute cardiac injury,Acute kidney injury (AKI),Secondary infection,Hypoproteinaemia,Acidosis,Hospital admission,ICU admission,Discharged (%),"ICU length of stay, days","Hospital length of stay, days",Days to Viral Clearance (Median),Mortality,Effective Mortality,Chest CT Improve,Chest CT Same,Chest CT Decline
1,0,China,Wuhan,191,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,                    ,Agni,Cynthia,12/29/2019,1/31/2020,33,Top-level,General,Positive only,End-point only,Both,Both,Yes,Both,All,Both,56,,,46,67,,62.30%,38%,,,,,,,,11.00,8.00,14.00,5.76%,,47.60%,30%,19.00%,8.00%,,3.00%,,1.68%,1.68%,12.00%,29.00%,1.68%,0.84%,94%,,,79%,,,23.00%,15.00%,23.03%,,4.71%,4.00%,,,,,,37.70%,34.55%,27.75%,6.2,4.5,9.5,128.0,,119.0,140.0,,,,1.00,0.60,1.30,206.00,,155.00,262.00,,,,,30.00,,,,7.40,,,,,,,,,,,,,,,94.76%,21.47%,,,,,,29.84%,24.08%,,21.47%,13.61%,16.75%,1.57%,,5.24%,,,58.64%,,53.93%,30.89%,,23.04%,19.90%,,19.37%,17.28%,14.66%,14.66%,11.52%,8.90%,,26.18%,71.73%,8.00,11.00,,28.27%,28.27%,,,
1,1,China,Wuhan,54,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,Non-survivors,Agni,,12/29/2019,1/31/2020,33,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,Both,Severe/Critical Only,Both,69,,,63,76,,70.37%,25.93%,,,,,,,,11.00,8.00,15.00,9.26%,,66.67%,48.15%,31.48%,24.07%,,7.41%,,0.00%,3.70%,20.37%,62.96%,3.70%,0.00%,94.44%,,,72.22%,,,25.93%,14.81%,27.78%,,3.70%,5.56%,,,,,,0.00%,22.22%,77.78%,9.8,6.9,13.9,126.0,,115.0,138.0,,,,0.60,0.50,0.80,165.50,,107.00,229.00,,,,,40.00,,,,11.00,,,,,,,,,,,,,,,98.15%,22.22%,,,,,,48.15%,66.67%,,61.11%,44.44%,57.41%,5.56%,,18.52%,,,100%,,98.15%,92.59%,,51.85%,70.37%,,50.00%,59.26%,50.00%,50.00%,37.04%,29.63%,,72.22%,0%,8,7.5,,100.00%,100.00%,,,
1,2,China,Wuhan,137,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,Survivors,Agni,,12/29/2019,1/31/2020,33,Subgroup,Survivors,Positive only,End-point only,Survivors only,Discharged only,Yes,Both,All,Both,52,,,45,58,,59.12%,43.07%,,,,,,,,11,8,13,4.38%,,40.15%,23.36%,13.87%,1.46%,,1.46%,,7.00%,0.00%,8.03%,16.06%,0.00%,0.73%,94.16%,,,81.75%,,,21.90%,15.33%,21.17%,,5.11%,2.92%,,,,,,52.55%,39.42%,8.03%,5.2,4.3,7.7,128.0,,120.0,140.0,,,,1.10,0.80,1.50,220.00,,168.00,271.00,,,,,27.00,,,,6.30,,,,,,,,,,,,,,,93.43%,21.17%,,,,,,22.63%,7.30%,,5.84%,1.46%,0.73%,0.00%,,0.00%,,,42.34%,,36.50%,6.57%,,11.68%,0.00%,,7.30%,0.73%,0.73%,0.73%,1.46%,0.73%,,8.03%,100%,7,12,,0.00%,0.00%,,,
2,0,China,Wuhan,199,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,,Arthur,,1/18/2020,2/3/2020,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,49,68,,60.30%,,,,,,,,,13,11,16,,,,,11.60%,,,,3.00%,,,,18.80%,,1%,91.50%,36.5,,,,,,,,,2.06%,4.25%,1%,,,,,,,,7,5.1,9.4,,,,,,,,0.9,0.6,1.2,207,,158,284,,,,,33,34,,,,,,,,,,,,,,,,,,95%,,,,,,,,,,,14.60%,16.10%,2%,33.70%,4.50%,,,,,,,,,,,,,,,,,,,na,10,15,,16.10%,,,,
2,1,China,Wuhan,99,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,With treatment (Lopinavir - Ritonavir),Arthur,Cynthia,1/18/2020,2/3/2020,16,Subgroup,With treatment,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,50,68,,61.60%,,,,,,,,,13,11,17,,,,,10.10%,,,,5.10%,,,,21.60%,,2%,89.90%,36.5,,,,,,,,,4.20%,9.50%,2.10%,,,,,,,,7.3,5.3,9.6,,,,,,,,0.8,0.6,1.4,201,,155,287,,,,,33,33,,,,,,,,,,,,,,,,,,94.90%,,94.90%,,,,,,,,,10.10%,14.10%,2%,32.30%,3.00%,,,0%,12.60%,,,,0%,2.10%,,,,3.20%,1.10%,,,,,na,6,14,,15.20%,,,,
2,2,China,Wuhan,100,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,Control,Arthur,,1/18/2020,2/3/2020,16,Subgroup,Control,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,48,68,,59.00%,,,,,,,,,13,10,16,,,,,13.00%,,,,1.00%,,,,16.00%,,0%,93.00%,36.5,,,,,,,,,0%,0%,0%,,,,,,,,6.9,4.9,9.1,,,,,,,,0.9,0.5,1.2,210,,163,269.5,,,,,34,34,,,,,,,,,,,,,,,,,,95%,,,,,,,,,,,19.10%,18.00%,2%,35.00%,6.00%,,,1%,27.30%,,,,1%,2.00%,,,,6.10%,6.10%,,,,,na,11,16,,17.00%,,,,
3,0,China,Wuhan,81,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,"Mostly care about CT scans and their features, seems sort of unique",Arthur,,12/20/2019,2/8/2020,50,Top-level,General,Positive only,End-point and active,Both,Both,No,Both,All,Both,50,49.5,11,,,,52%,38%,38%,,,,,,,,,,,,26%,15%,12%,10%,,11%,5%,,4%,16%,,,,73%,37.93,37.93,59%,42%,6%,19%,9%,9%,,4%,5%,1%,,,,18.51%,,,,8.1,4.7,11.5,123.9,,111.9,135.9,1,,,1.1,0.8,1.4,212.2,,112.5,311.9,11.9,8.3,15.5,,46.2,40.8,,47.6,,,,,,,,,,26.40%,,53%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,77%,,12.2,,3.70%,4.58%,,,
3,1,China,Wuhan,15,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Subgroup 1,Ryan,,12/20/2019,2/8/2020,50,Subgroup,Subclinical,Positive only,End-point and active,Both,Both,No,Both,All,Both,,44.9,9,,,,27.00%,0.00%,0.00%,,,,,,,,,,,,27.00%,13%,20%,20%,,7%,7%,,0%,7%,,,,0.00%,,36.6,0.00%,0.00%,0.00%,0.00%,0.00%,0%,,0%,0.00%,0%,,,,100%,0%,0%,0%,8,5.5,10.5,125.1,,111.6,138.6,1,,,1.1,0.8,1.4,202.9,,135.5,270.3,9.2,8.6,9.8,,30.8,30.2,,6.9,,,,,,,,,,16%,,27%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,
3,2,China,Wuhan,21,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Subgroup 2,Ryan,,12/20/2019,2/8/2020,50,Subgroup,Scans done <= 1 week after symptom onset,Positive only,End-point and active,Both,Both,No,Both,All,Both,,48.8,13,,,,52.00%,38.00%,38.00%,,,,,,,,,,,,24.00%,5%,10%,5%,,14%,5%,,0%,15%,,,,86.00%,,38.1,71.00%,43.00%,10.00%,14.00%,5.00%,9%,,5.00%,10.00%,5%,,,,0%,,,,7.8,4.2,11.4,126.7,,113.3,140.1,1,,,1,0.7,1.3,213.5,,112.7,314.3,14.1,9.8,18.4,,50.6,47.7,,61.4,,,,,,,,,,34.40%,,62%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,
3,3,China,Wuhan,30,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Subgroup 3,Ryan,,12/20/2019,2/8/2020,50,Subgroup,Scans done 1-2 weeks after symptom onset,Positive only,End-point and active,Both,Both,No,Both,All,Both,,52.3,13,,,,67.00%,47.00%,47.00%,,,,,,,,,,,,30.00%,23%,10%,10%,,10%,7%,,10%,20%,,,,90.00%,,38.2,70.00%,43.00%,7.00%,20.00%,13.00%,5%,,3.00%,7.00%,0%,,,,0%,,,,8.4,4.9,11.9,119.6,,106.8,132.4,1,,,1.1,0.8,1.4,206.8,,110.7,302.9,11.9,8,15.8,,48.7,42.7,,71.3,,,,,,,,,,29.60%,,60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.67%,,,,
3,4,China,Wuhan,15,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Subgroup 4,Ryan,,12/20/2019,2/8/2020,50,Subgroup,Scans done >2 weeks after symptom onset,Positive only,End-point and active,Both,Both,No,Both,All,Both,,49.5,11,,,,47.00%,60.00%,60.00%,,,,,,,,,,,,20.00%,13%,13%,7%,,13%,0%,,0%,20%,,,,93.00%,,38.5,80.00%,80.00%,7.00%,40.00%,13.00%,13%,,7.00%,0.00%,0%,,,,0%,,,,8.2,4,12.4,124.8,,115.7,133.9,1,,,1.1,0.8,1.4,230.5,,95.7,365.3,na,na,na,,50.6,37.8,,49.8,,,,,,,,,,21.60%,,53%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.67%,,,,
4,0,China,Zhejiang,149,"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China",Journal of Infection,Yang et al.,https://reader.elsevier.com/reader/sd/pii/S0163445320300992?token=9163263C94899C48B765689929BEFCC2B1AD126DCC83E3753645A68BB99CF497BB124D1BB7AB61F22F586414124183AD,English,"Retrospective multi-center cohort study, Only positive cases, most not severe, over half still in hospital at end, until Feb 15th, 2020",Matthew,Cynthia,1/17/2020,2/15/2020,29,Top-level,,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Both,,45.11,,,,0%,54.40%,89.90%,53.69%,32.89%,,,,,6.83,,,,,,34.90%,,,,,,,,,,,,,76.50%,37.86,,58.40%,1.34%,8.72%,32.20%,3.36%,,,7.38%,1.34%,,14.09%,14.09%,,,,,,4.56,2.08,6.64,,,,,,,66.07,1.21,0.53,1.89,174.5,,96.25,252.75,9.9,3.95,15.85,2.6,20,23,5.83,7.25,,,,,,,,,,,,,,,,22.82%,93.96%,,,,,,,12.75%,,89.93%,1.34%,,0%,,3.36%,,,,,,,,,,,,,,,,,100%,0%,48.99%,,,,0.00%,0.00%,,,
5,0,China,Wuhan,21,Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia,Radiology,Pan et. al.,https://pubs.rsna.org/doi/full/10.1148/radiol.2020200370,English,,Ryan,,1/12/2020,2/6/2020,25,Top-level,Non-severe only,Positive only,End-point only,Both,Discharged only,No,ΝΑ,Mild only,Both,40,40,9,30,57,,29.00%,,,,,,,,,6,5,7,,,,,,,,,,,,,,,,86%,,,57%,,,,24%,52%,,,,43%,,29%,,,0%,0%,0%,4.9,4.1,5.7,,,,,1,,,1.4,1,1.8,,,,,,,,3.1,42,32,,17.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,17,,0.00%,0.00%,,,
6,0,China,Beijing,77,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,,Ryan,,1/21/2020,2/7/2020,17,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,52,52,20,,,2.60%,44.16%,89.60%,70.10%,19.50%,4,4,3.5,6,5,5,3,6,,,31.20%,20.80%,7.80%,11.70%,,7.79%,,,6.50%,,,,,85.70%,,,63.64%,20.80%,13.00%,,27.30%,27.30%,,1.30%,7.79%,9.10%,6.50%,,,0.00%,25.97%,,,4.04,3.48,5.58,137,,125,145,0,,,,,,190,,149,245,,,,,28,29,,17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.90%,,2.60%,1.30%,32.47%,,,2.60%,3.90%,,,100.00%,,83.10%,,13,,6.49%,7.24%,,,
6,1,China,Beijing,58,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,Non-severe,Ryan,,1/21/2020,2/7/2020,17,Subgroup,Non-severe only,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,45,45,17,,,3.50%,40.40%,91.20%,77.20%,14%,5,5,3.5,6,5,5,4,6,,,24.60%,14%,7.00%,5.30%,,5.30%,,,3.50%,,,,,82.50%,,,57.90%,14%,17.50%,,33.30%,33.30%,,1.80%,5.30%,7%,9%,,,0%,0%,0%,0.00%,3.95,3.45,4.64,139,,127,144,0,,,,,,189,,152,245,,,,,28,28,,13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,0.00%,0.00%,33.30%,,,1.80%,0.00%,,,100%,,93.10%,,12,,0.00%,0.00%,,,
6,2,China,Beijing,20,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,severe,Ryan,,1/21/2020,2/7/2020,17,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,69,69,15,,,0%,55.00%,85%,50%,35%,3.5,3.5,3,4,6,6,5,7,,,50%,40%,10.00%,30.00%,,15.00%,,,15%,,,,,95%,,,80.00%,40%,0.00%,,10.00%,10.00%,,0.00%,15.00%,15%,0%,,,0%,100%,,,5.92,3.68,7.59,137,,119,148,0,,,,,,198,,134,272,,,,,32,36,,55,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.00%,,10.00%,5.00%,30.00%,,,5.00%,15.00%,,,100%,,50%,,18.5,,25.00%,33.33%,,,
7,0,China,Wuhan,36,Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study,MedrXiv,Yang et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20036780v1.full.pdf,English,"Conditioned on patients who required invasive ventilation, so high death rate",Ryan,,2/12/2020,3/2/2020,19,Top-level,Severe,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,69.4,69.4,21.16368,,,,83.30%,,,,,,,,,,,,,,,38.90%,27.80%,33.30%,,19.40%,5.60%,,,19.44%,,,,,,,,100%,,,,,,,,,,,,,100%,0%,100.00%,14,6.9,21.1,122.4,,104.3,140.5,0,,,0.6,0.3,0.9,156,,99.8,213,,,,12.7,34.5,30.5,,,,,,,,,,,,,,,,,,94.40%,77.78%,,,,,,80.60%,80.60%,,,0%,100%,,,61.10%,,,,,,,,19.44%,,,,,22.22%,,,,100%,100%,na,,,,63.89%,,,,
8,0,Italy,Nationwide,3200,"Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020",COVID-19 Surveillance Group,Palmieri et. al.,https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf,English,Conditioned on deceased patients only,Ryan,,3/1/2020,3/20/2020,19,Subgroup,Severe,Positive only,End-point only,Non-Survivors only,Both,No,ΝΑ,Severe/Critical Only,NA,78.5,80,,73,85,,70.60%,,,,,,,,4,,,,,,98.80%,73.80%,33.90%,30.10%,,13.70%,19.50%,,20.20%,3.70%,,,,76.00%,,,40%,73.00%,,,,,,8.00%,,,,,,0.00%,100.00%,0.00%,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,84%,54%,,,,,,,,,,,,,,,,,,96.50%,,96.50%,,,,,,10.40%,29.20%,8.50%,,,100.00%,50.00%,0%,5,4,,100.00%,100.00%,,,
9,0,China,Zhejiang,91,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",,,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,"Retrospective, multicentre study until  until Feb 16th, 2020, contains age breakdowns, breakdown of lab measurements by mild vs severe",Matthew,,1/20/2020,2/16/2020,27,Top-level,,Positive only,End-point and active,Survivors only,Both,Yes,,All,NA,50,,,36.5,57,0%,40.66%,98.90%,34.07%,8.79%,,6,,,,,,,,,,16.48%,8.79%,,,,,,,,,,,71.43%,,,60.44%,3.30%,7.69%,32.97%,5.49%,43.96%,,23.08%,6.59%,25.27%,,,,,90.10%,9.90%,,4.99,4.25,5.69,135,,125,145,1,,,1.35,0.98,1.66,196,,142,238,,,,2.91,18,21,,6.81,,,,,,,,,,,,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,9.89%,34.07%,,,,0.00%,0.00%,,,
9,1,China,Zhejiang,9,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",,,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,"Retrospective, multicentre study until  until Feb 16th, 2020, contains age breakdowns, breakdown of lab measurements by mild vs severe",Matthew,,1/20/2020,2/16/2020,27,Subgroup,Severe Cases,Positive only,End-point and active,Survivors only,Both,,,Severe/Critical Only,,66,,,54,80,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,0.00%,,5.23,3,5.82,130,,118,142,1,,,0.9,0.7,1.3,152,,127,208,,,,3.32,19.9,27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,na,,,,0.00%,,,,
9,2,China,Zhejiang,82,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",,,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,"Retrospective, multicentre study until  until Feb 16th, 2020, contains age breakdowns, breakdown of lab measurements by mild vs severe",Matthew,,1/20/2020,2/16/2020,27,Subgroup,Mild Cases,Positive only,End-point and active,Survivors only,Both,,,Mild only,,49,,,35.3,56,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,100.00%,,4.97,4.02,5.65,135,,126,147,1,,,1.4,1.05,1.75,198,,144,248,,,,2.8,18,21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,na,,,,0.00%,,,,
10,0,China,Seven hospitals,62,"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Limitation: most patients still in hospital when study concluded,Ryan,,1/10/2020,1/26/2020,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,41,41,,32,52,,56%,37%,37%,,4,4,3,5,2,2,1,4.3,,,32.00%,8.00%,2.00%,2%,,2%,,,2%,11%,3%,,,77.00%,,,81.00%,3.00%,34.00%,,52%,52%,,8.00%,,,,,,,,,,4.7,3.5,5.8,137,,128.8,152.3,0,,,1,0.8,1.5,176,,135.8,215.5,,,,2.9,22,26,,,,,,,,,,,,34%,,16%,,,,45%,89%,6%,,,,,26%,26%,,,,1.61%,,,,,,,,,2.00%,,,,,,,,,,,100.00%,1.61%,2%,,,,0.00%,,,,
10,1,China,Seven hospitals,33,"Clinical Findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Subgroup >10 days,Ryan,,1/10/2020,1/26/2020,16,Subgroup,> 10 days after onset,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,45,45,,37,54,,58.00%,27%,27%,,3,3,3,4,6.5,6.5,5,9,,,39%,12.00%,2.00%,3.00%,,3%,,,0.00%,12.00%,3%,,,73.00%,,,82.00%,6.00%,45.00%,,58.00%,58.00%,,9.00%,,,,,,,,,,4.5,3.1,6.1,137.5,,129,149.5,0,,,1,0.7,1.4,172.5,,128.8,202.8,,,,2.8,22.5,27.5,,,,,,,,,,,,36%,,15%,,,,48.00%,94%,9%,,,,,33.00%,33.00%,,,,3%,,,,,,,,,3.00%,,,,,,,,,,,100.00%,3.00%,3%,,,,0.00%,,,,
10,2,China,Seven hospitals,29,"Clinical Findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Subgroup <=10 days,Ryan,,1/10/2020,1/26/2020,16,Subgroup,<=10 days after onset,Positive only,Active only,Both,Non-discharged only,Yes,Both,All,Both,39,39,,31,50,,55.00%,48%,48%,,5,5,4,7,2,2,1,2,,,24.00%,3.00%,3.00%,0.00%,,0%,,,0.00%,10.00%,3%,,,83.00%,,,79.00%,0.00%,21.00%,,45.00%,45.00%,,0.00%,,,,,,,,,,4.9,3.9,5.7,136.5,,127.3,153.8,0,,,1,0.9,1.5,186,,149,228,,,,2.9,22,25,,,,,,,,,,,,30.40%,,17%,,,,41.00%,83%,3%,,,,,17.00%,17.00%,,,,0%,,,,,,,,,0.00%,,,,,,,,,,,100.00%,0.00%,0%,,,,0.00%,,,,
11,1,China,Guangzhou,16,Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study,Journal of Infection,Deng et. al.,https://reader.elsevier.com/reader/sd/pii/S0163445320301134?token=517FFF6E19C9C17E84812ED8214D6754AB25026D7C243B1030EA49CE191BCDD9FFAAAFB89B027FDC2CB8F9A14AA9655C,English,Combination group - no exact mortality outcomes,Agni,,1/17/2020,2/29/2020,43,Subgroup,Combination therapy group,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,,41.8,,,,,43.80%,,,,,,,,,,,,,,12.50%,18.80%,12.50%,12.50%,,0%,,0%,6.20%,12.50%,,,,,,,,,,,,,,,,,,,,,,31.20%,,5.34,3.52,7.16,,,,,0,,,1.83,1.01,2.65,194.8,,139.7,249.9,9.23,4.26,14.2,,,,,,,,,,,,,,,,,,,,,56.30%,100%,100%,,,,,6.20%,68.80%,,31.20%,,0%,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
11,2,China,Guangzhou,17,Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study,Journal of Infection,Deng et. al.,https://reader.elsevier.com/reader/sd/pii/S0163445320301134?token=517FFF6E19C9C17E84812ED8214D6754AB25026D7C243B1030EA49CE191BCDD9FFAAAFB89B027FDC2CB8F9A14AA9655C,English,Monotherapy group - no exact mortality outcomes,Agni,,1/17/2020,2/9/2020,23,Subgroup,Monotherapy group,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,,47.25,,,,,58.80%,,,,,,,,,,,,,,11.76%,11.70%,17.60%,17.60%,,5.90%,,0%,11.70%,5.90%,,,,,,,,,,,,,,,,,,,,,,35.30%,,5.04,3.96,6.12,,,,,0,,,1.36,0.84,1.88,198.6,,121.4,275.8,9.51,4.65,14.37,,,,,,,,,,,,,,,,,,,,,70.60%,100%,100%,,,,,41.20%,76.50%,,35.30%,,0%,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
12,0,China,Jiangsu,620,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,Has dynamic data (i.e. how vital signs evolved during progression of disease) at group level,Ryan,Irra,1/10/2020,2/18/2020,39,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,NA,,44.48,17.16,,,,52.60%,89.84%,35.00%,41.50%,6.91,6.91,,,,4.23,,,4.03%,4.84%,,15.48%,6.45%,2.10%,,,1.10%,,0.60%,1.00%,,,,65.97%,37.05,,55.32%,2.58%,,26.61%,,,,8.56%,,1.90%,,,,15.65%,75.81%,5.30%,3.20%,5.21,3.24,7.18,135.33,,115.86,154.80,0,40.07,,1.36,0.72,2,190.47,,127.40,253.54,,,,3.36,31.03,32.26,,,,,,,,,,616.07,427.15,,,,,,,53.55%,92.90%,,,,,,22.90%,25.20%,34.80%,2.90%,5.30%,0.80%,0.00%,22.90%,0.00%,,,,,8.55%,,,,0.32%,,,,,,,,100.00%,3.20%,40.60%,,,,0.00%,0.00%,,,
12,1,China,Jiangsu,97,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,Asymptotic/mild,Ryan,Irra,1/10/2020,2/18/2020,39,Subgroup,Asymptomatic/Mild,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,,35.96,19.88,,,,45.40%,96.90%,24.70%,59.80%,4.49,4.49,,,,4.38,,,6.20%,5.20%,,11.30%,9.30%,3.10%,,,0.00%,,0%,2.90%,,,,23.70%,36.77,,29.90%,1.00%,,12.40%,,,,4.10%,,1.00%,,,,100.00%,0.00%,0.00%,0.00%,5.68,3.80,7.56,136.26,,118.06,154.46,0,41.11,,1.76,1.04,2.48,218.88,,142.36,295.40,,,,3.38,26.78,27.31,,,,,,,,,,805.05,656.73,,,,,,,15.50%,85.60%,,,,,,7.20%,9.30%,16.50%,0.00%,0.00%,0.00%,0.00%,7.20%,0.00%,,,,,0.00%,,,,0.00%,,,,,,,,100.00%,0.00%,36.10%,,,,0.00%,0.00%,,,
12,2,China,Jiangsu,470,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,Moderate,Ryan,Irra,1/10/2020,2/18/2020,39,Subgroup,Moderate,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Both,,44.47,15.62,,,,52.60%,88.90%,36.60%,39.40%,5.10,5.10,,,,4.19,,,4.00%,4.10%,,14.30%,4.90%,1.30%,,,1.30%,,0.60%,5.70%,,,,72.60%,37.09,,58.90%,2.70%,,24.70%,,,,9.20%,,2.30%,,,,0.00%,100.00%,0.00%,0.00%,5.07,3.35,6.79,135.55,,115.62,155.48,0,39.98,,1.35,0.78,1.92,186.82,,129.11,244.53,,,,3.26,31.19,32.32,,,,,,,,,,594.17,385.96,,,,,,,56.80%,93.60%,,,,,,18.90%,23.00%,34.00%,0.90%,1.30%,0.00%,0.00%,18.90%,0.00%,,,,,0.00%,,,,0.00%,,,,,,,,100.00%,2.10%,44.30%,,,,0.00%,0.00%,,,
12,3,China,Jiangsu,53,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,Critical,Ryan,Irra,1/10/2020,2/18/2020,39,Subgroup,Severe/Critical,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,,60.09,13.86,,,,66.00%,84.90%,39.60%,26.40%,4.44,4.44,,,,4.42,,,0.00%,1.90%,,34.00%,15.10%,7.50%,,,1.90%,,1.90%,4.80%,,,,84.90%,37.2,,69.80%,11.30%,,41.50%,,,,11.30%,,0%,,,,0.00%,0.00%,62.26%,37.74%,5.46,1.89,9.03,131.24,,113.51,148.97,0,38.58,,0.7,0.38,1.02,160.95,,104.91,216.99,,,,4.19,39.32,42.86,,,,,,,,,,364.50,231.00,,,,,,,94.30%,100.00%,,,,,,86.80%,73.60%,75.50%,26.40%,50.90%,9.40%,0.00%,86.80%,0.00%,,,,,100.00%,,,,3.80%,,,,,,,,100.00%,18.90%,17.00%,,,,0.00%,0.00%,,,
13,0,China,Nationwide,1099,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,"Clinical separated into severe vs. non-severe (next two rows), based on guidelines for community-acquired pneumonia, and end-point vs non-endpoint",Ted,Irra,12/11/2019,1/29/2020,49,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,47,,,35,58,,58.10%,,31.30%,,,4,2,7,,,1,,12.60%,,,15%,7.40%,2.50%,,1.10%,0.90%,,0.70%,,,,,88.70%,,38.3,67.80%,18.70%,13.60%,33.70%,14.90%,38.10%,4.80%,3.80%,5%,,13.90%,11.50%,,,84.30%,15.70%,,4.7,3.5,6,134,,119,148,,,,1,0.7,1.3,168,,132,207,,,,,,,,,,,,,,,,,,,,,,,,58%,35.80%,,,,,,18.60%,13.10%,,41.30%,5.10%,2.30%,0.50%,,0.80%,,,,,,3.40%,,,1.10%,,,,0.50%,,,,,5.00%,5.00%,,12,,1.40%,21.88%,,,
13,1,China,Nationwide,926,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,,Ted,Irra,12/11/2019,1/29/2020,49,Subgroup,Non-Severe,Positive only,End-point and active,Both,Both,Yes,Both,Mild only,Non-ventilation only,45,,,34,57,,58.20%,,31.60%,,,4,2.8,7,,,,,11.80%,,,13.40%,5.70%,1.80%,,0.60%,0.80%,,0.50%,,,,,88.10%,,38.3,67.30%,15.10%,13.40%,33.40%,14.50%,37.80%,5.10%,3.50%,4.60%,,14%,10.80%,,,,,,4.9,3.8,6,135,,120,148,,,,1,0.8,1.4,172,,139,212,,,,,,,,,,,,,,,,,,,,,,,,53.80%,33.80%,,,,,,13.70%,9.30%,,35.70%,0%,0%,0%,,0%,,,,,,1.10%,,,0.10%,,,,0.10%,,,,,2.40%,5.40%,,11,,0.10%,1.82%,,,
13,2,China,Nationwide,173,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,,Ted,Irra,12/11/2019,1/29/2020,49,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,52,,,40,60,,57.80%,,30.00%,,,4,2,7,,,,,16.90%,,,23.70%,16.20%,5.80%,,3.50%,1.70%,,1.70%,,,,,92%,,38.5,70.50%,37.60%,15%,35.30%,17.30%,39.90%,3.50%,5.80%,6.90%,,13.30%,15%,,,,,,3.7,3,6.2,128,,112,141,,,,0.8,0.6,1,137.5,,99,179.5,,,,,,,,,,,,,,,,,,,,,,,,80.30%,46.20%,,,,,,44.50%,33.50%,,71.10%,32.40%,14.50%,2.90%,,5.20%,,,,,,15.60%,,,6.40%,,,,2.90%,,,,,19.10%,2.90%,,13,,8.10%,73.64%,,,
13,3,China,Nationwide,67,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,,Ted,Irra,12/11/2019,1/29/2020,49,Subgroup,ICU/Venitlation/Death,Positive and Negative/Unconfirmed,End-point and active,Both,Both,Yes,Both,All,Both,63,,,53,71,,67.20%,,35.70%,,,4,1,7.5,,,,,25.80%,,,35.80%,26.90%,9.00%,,10.40%,1.50%,,3.00%,,,,,88.10%,,38.5,68.70%,53.70%,12%,29.90%,9.00%,32.80%,3.00%,6.00%,4.50%,,9%,11.90%,,,,,,6.1,4.9,11.1,125,,105,140,,,,0.7,0.6,0.9,156.5,,114.2,195,,,,,,,,,,,,,,,,,,,,,,,,89.60%,53.70%,,,,,,52.20%,40.30%,,88.10%,43.30%,37.30%,7.50%,,11.90%,,,,,,40.30%,,,13.40%,,,,40.30%,,,,,82.10%,1.50%,,14.5,,22.40%,93.72%,,,
13,4,China,Nationwide,1032,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,,Ted,Irra,12/11/2019,1/29/2020,49,Subgroup,Not (ICU/Ventilation/Death),Positive and Negative/Unconfirmed,End-point and active,Survivors only,Both,Yes,Non-ICU only,All,Both,46,,,35,57,,57.50%,,31.10%,,,4,2,7,,,,,11.80%,,,13.70%,6.10%,2.00%,,0.50%,0.90%,,0.60%,,,,,88.80%,,38.3,67.70%,16.40%,14%,33.90%,15.30%,38.50%,4.90%,3.70%,5.00%,,14.20%,11.40%,,,,,,4.7,3.5,5.9,134,,120,148,,,,1,0.7,1.3,169,,133,207,,,,,,,,,,,,,,,,,,,,,,,,55.90%,34.60%,,,,,,16.40%,11.30%,,38.30%,2.60%,0.00%,0.00%,,0.10%,,,,,,1.00%,,,0.30%,,,,1.00%,,,,,0.00%,5.20%,,12,,0.00%,0.00%,,,
16,0,China,Wuhan,41,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,Fatigue and Myalgia counted as one. High flow cannula and noninvasive ventilation counted as one. Invasive and ECMO counted as one.,Kim,Irra,12/16/2019,1/2/2020,17,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,49,,,41,58,,73%,66%,66%,,,,,,,7,4,8,7%,,32%,15%,20%,15%,,2%,2%,,,2%,29%,,,98%,,,76%,55%,,28%,44%,44%,,3%,,,,,,,,,,6.2,4.1,10.5,126,,118,140,1,,,0.80,0.60,1.10,164.5,,131.5,263,11.7,9.5,13.9,5,32,34,,,,,,,,,,,,,,,,,,100%,93%,,,,,,22%,,66%,24%,24%,5%,5%,,7%,,,,29%,,29%,,12%,,,,,7%,10%,,,100%,32%,68%,,,,15.00%,18.07%,,,
16,1,China,Wuhan,13,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,,Kim,,12/16/2019,1/2/2020,17,Subgroup,ICU care,Positive only,End-point and active,Both,Both,Yes,ICU only,All,Both,49,,,41,61,,85%,69%,69%,,,,,,,7,4,8,0%,,38%,15%,8%,23%,,8%,0%,,,0%,62%,,,100%,,,85%,92%,,38%,54%,54%,,0%,,,,,,,,,,11.3,5.8,12.1,122,,111,128,1,,,0.40,0.20,0.80,196,,165,263,14,11.9,32.9,10.6,49,44,,,,,,,,,,,,,,,,,,100%,92%,,,,,,46%,,8%,62%,62%,15%,15%,,23%,,,,85%,,85%,,31%,,,,,23%,31%,,,100%,100%,54%,,,,38.00%,41.30%,,,
16,2,China,Wuhan,28,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,,Kim,,12/16/2019,1/2/2020,17,Subgroup,No ICU care,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,All,Both,49,,,41,57.5,,68%,64%,64%,,,,,,,7,4,8.5,11%,,29%,14%,25%,11%,,0%,4%,,,4%,14%,,,96%,,,71%,37%,,23%,39%,39%,,4%,,,,,,,,,,5.7,3.1,7.6,130.5,,120,140,1,,,1.00,0.70,1.10,149,,131,263,10.8,9.4,12.3,4.4,27,34,,,,,,,,,,,,,,,,,,100%,93%,,,,,,11%,,93%,7%,7%,0%,0%,,0%,,,,4%,,4%,,4%,,,,,0%,0%,,,100%,0%,75%,,,,4.00%,5.06%,,,
17,0,China,Wuhan,99,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study",The Lancet,Chen et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext?from=Qikan_Academic_Index,English,,Kim,Irra,1/1/2020,1/20/2020,19,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,55.5,13.1,,,,68%,49%,,,,,,,,,,,,,33%,,12%,40%,,1%,1%,,,17%,,,,83%,,,82%,31%,8%,,11%,,,2%,1%,,5%,,,,,,,7.5,3.9,11.1,129.8,,111.5,144.6,1,,,0.9,0.4,1.4,213.5,,,,15.1,7.8,22.4,5,39,34,,51.4,,,,,,,,,,,,,,,,71%,76%,,,,,,,27%,76%,,13%,4%,3%,19%,9%,,,,,,,,,,,,,,,,,100%,23%,31%,,,,11.00%,26.19%,,,
18,1,China,Zhejiang,26,The Clinical Characteristics of Myocardial injury 1 in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease,Journal of Infection,Zhou et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301493,English,focus on cardiac biomarkers,Agni,Irra,2/5/2020,2/13/2020,8,Subgroup,Severe,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,63,,,58,69,,46.15%,,,,,,,,,,,,,,,,,0%,,,,,,,100%,,,,,,,,,,,,,,,,,,,,0%,100%,0%,5.93,4.77,7.45,,,,,0,,64.2,,,,,,,,,,,,34,32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,,
18,2,China,Zhejiang,8,The Clinical Characteristics of Myocardial injury 1 in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease,Journal of Infection,Zhou et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301493,English,focus on cardiac biomarkers,Agni,Irra,2/5/2020,2/13/2020,8,Subgroup,Critical,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,67,,,66,75,,62.50%,,,,,,,,,,,,,,,,,0%,,,,,,,100%,,,,,,,,,,,,,,,,,,,,0%,0%,100%,9.32,6.37,10.99,,,,,0.00%,,82.6,,,,,,,,,,,,49,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,,
19,0,China,Wuhan,138,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,"As of Feb 3, so much data regarding outcome can be different",Léonard,Irra,1/1/2020,2/3/2020,33,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,56,56,,42,68,29%,54.30%,8.70%,8.70%,,,,,,7,7,4,8,,,46.40%,31.20%,10.10%,14.50%,,2.90%,7.20%,,2.90%,1.40%,,,,98.60%,,,59.40%,31.20%,6.50%,26.80%,34.80%,69.60%,,10.10%,10.10%,39.90%,,,,0%,26%,0%,26.08%,4.5,3.3,6.2,,,,,1.00,,72.00,0.8,0.60,1.10,163.00,,121.00,191.00,9.8,8.4,14.1,3,24.00,31.00,,,,,,,,,,,,,,,,,,64.40%,89.90%,,,,,,44.90%,,76.81%,,10.90%,12.32%,2.90%,44.90%,,,,,19.60%,,19.60%,,,8.70%,,,7.20%,3.60%,,,,100%,26%,34.10%,10,10,,4.30%,11.20%,,,
19,1,China,Wuhan,36,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,ICU,Ryan,Irra,1/1/2020,2/3/2020,33,Subgroup,Non-ICU,Positive only,End-point and active,Survivors only,Both,Yes,ICU only,All,Both,66,66,,57,78,2.80%,61.10%,13.90%,13.90%,,,,,,8,8,4.5,10,,,72.20%,58.30%,22.20%,25%,,8.30%,11.10%,,5.60%,0%,,,,100.00%,,,58.30%,63.90%,8.30%,22.20%,33.30%,80.60%,,16.70%,11.10%,66.70%,,,,0%,0%,0%,0%,6.60,3.60,9.80,,,,,1.00,,80.00,0.8,0.50,0.90,142.00,,119.00,202.00,11.5,9.6,18.6,4.6,35.00,52.00,,,,,,,,,,,,,,,,,,,94.40%,,,,,,,,11.11%,,42%,47%,11.10%,72.20%,,,,,61.10%,,61.10%,,,30.60%,,,22.20%,8.30%,,,,100%,100%,25.00%,10,,,17.00%,40.48%,,,
19,2,China,Wuhan,102,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,Non-ICU,Ryan,Irra,1/1/2020,2/3/2020,33,Subgroup,ICU,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Severe/Critical Only,Non-ventilation only,51,51,,37,62,38.20%,52%,6.90%,6.90%,,,,,,6,6,3,7,,,37.30%,21.60%,5.90%,10.80%,,1%,5.90%,,2%,2%,,,,98.00%,,,59.80%,19.60%,5.90%,28.40%,35.30%,65.70%,,7.80%,9.80%,30.40%,,,,0%,100%,0%,100%,4.30,3.30,5.40,,,,,1.00,,71.00,0.9,0.60,1.20,165.00,,125.00,188.00,9.3,8.2,12.8,2.7,23.00,39.00,,,,,,,,,,,,,,,,,,,88.20%,,,,,,,,100%,,0%,0%,0%,35.30%,,,,,4.90%,,4.90%,,,1.00%,,,2%,2.00%,,,,100%,0%,37%,,10,,0.00%,0.00%,,,
20,0,China,Beijing,13,"Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China",JAMA,Chang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761043,English,No concrete mortality data,Agni,,1/16/2020,2/4/2020,19,Top-level,General,Positive only,Active only,Survivors only,Both,No,ΝΑ,Mild only,NA,34,,,34,48,,77%,,,,,,,,,,,,,,,,,,,,,,,,,,,92.31%,,38.4,46.30%,,23.10%,,23.10%,,61.50%,7.70%,,,,,,,,0%,0%,5.83,3.51,8.15,147,,134.9,159.1,0,43.2,,1.58,0.927,2.233,199,,126.5,271.5,,,,3.67,,,,147,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
21,0,China,Beijing,51,Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia,Radiology,Song et al.,https://pubs.rsna.org/doi/pdf/10.1148/radiol.2020200274,English,No data on treatments,Ryan,,1/20/2020,1/27/2020,7,Top-level,General,Positive only,Active only,Survivors only,Discharged only,No,ΝΑ,Mild only,NA,,49,16,,,,49%,98%,,,,,,,,4,,,7%,,22%,10%,6%,2%,,0%,0%,0%,0%,4%,,,,96%,,,47%,14%,16%,,16.50%,16.50%,,10%,6%,,,,,,0%,0%,0%,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,na,,,,,,,,
22,0,China,Northeast Chongqing,135,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,T-tests for difference in values between mild and severe cases,Ted,Irra,1/23/2020,2/8/2020,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,47,,,36,55,,53.40%,88.90%,,17.00%,,,,,,,,,6.70%,,31.90%,9.60%,8.90%,5.20%,,0%,3%,,,,,,,88.90%,,,76.50%,13.30%,32.50%,8.80%,32.50%,32.50%,,13.30%,3%,,,,,,70%,30%,,5.4,4.1,7.8,133,,122,147,1,,,1.1,0.7,1.5,158,,131,230,8.6,5.9,13.7,3.5,26,33.4,,10.5,,,,,,,,,,,,,,,,43.70%,100%,,,,,,26.70%,,,,25.20%,0.70%,0%,,3.70%,,,,,,15.60%,,,,,,7.40%,3.70%,5.20%,,,,,11.11%,,,,0.74%,6.24%,,,
22,1,China,Northeast Chongqing,95,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,,Ted,Irra,1/23/2020,2/8/2020,16,Subgroup,Mild,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Both,44,,,33,49,,54.70%,90.50%,,18.90%,,,,,,,,,8.40%,,16.30%,9.40%,3.10%,1%,,0%,1%,,,,,,,90.10%,,,70.50%,9.50%,24.20%,5.30%,26.30%,26.30%,,5.30%,4.20%,,,,,,,,,5.5,4,8,134,,124,147,1,,,1.2,0.8,1.6,170,,136,234,8.6,5.6,14,3.6,21.7,22.4,,7.7,,,,,,,,,,,,,,,,25%,95%,,,,,,15.80%,,,,7.40%,0%,0%,,1%,,,,,,1.10%,,,,,,8.40%,4%,0%,,,,,10.53%,,,,0.00%,0.00%,,,
22,2,China,Northeast Chongqing,40,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,,Ted,Irra,1/23/2020,2/8/2020,16,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,56,,,52,73,,52.50%,85.00%,,12.50%,,,,,,,,,2.50%,,70%,10%,22.50%,15%,,10%,7.50%,,,,,,,85.00%,,,87.50%,18.90%,27.50%,17.50%,47.50%,47.50%,,32.50%,0%,,,,,,,,,5.2,4.9,6.9,130,,130,143,1,,,0.8,0.6,1,147,,118,213,9.8,7.8,15.6,4.1,26.6,33.6,,91,,,,,,,,,,,,,,,,87.50%,40%,,,,,,52.50%,,,,67.50%,2.50%,0%,,10%,,,,,,50%,,,,,,5%,2.50%,2.50%,,,,,12.50%,,,,2.50%,16.67%,,,
23,0,China,Wuhan,17,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,Overall,Ted,,1/22/2020,2/10/2020,19,Top-level,General,Positive only,End-point and active,Survivors only,Both,No,ΝΑ,All,NA,,45.1,12.8,,,,53%,65%,,,,,,,,,,,18%,18%,18%,6%,0%,0%,,0%,0%,0%,0%,18%,,,,71%,,,77%,,,17.60%,24%,47%,,12%,,,,,,,,,,6.2,3.7,8.7,140.5,,127.4,153.6,1,,,1.1,0.6,1.6,227.1,,115.5,338.7,17.7,,,4.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,29%,,8.4,,0.00%,0.00%,,,
23,1,China,Wuhan,5,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,Discharged patients only,Ryan/Ted,,1/22/2020,2/10/2020,19,Subgroup,Discharged,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,NA,,34.8,9.2,,,,80%,100%,,,,,,,,,,,40%,20%,40%,0%,0%,0%,,0%,0%,0%,0%,40%,,,,80%,,,60%,,,0%,60%,60%,,0%,,,,,,,,,,6.3,4.8,7.8,146.3,,139.6,153,1,,,1.7,1.3,2.1,295,,149.3,440.7,12.2,,,3.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,8.6,,0.00%,0.00%,,,
23,2,China,Wuhan,12,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,Nondischarged patients,Ryan/Ted,,1/22/2020,2/10/2020,19,Subgroup,Non-Discharged,Positive only,Active only,Survivors only,Non-discharged only,No,ΝΑ,All,NA,,49.4,11.7,,,,41.70%,50%,,,,,,,,,,,8.30%,16.70%,8.30%,8.30%,0%,0%,,0%,0%,0%,0%,8.30%,,,,66.70%,,,83.30%,,,25%,16.70%,41.70%,,16.70%,,,,,,,,,,6.1,3.2,9,138.5,,124.1,152.9,1,,,0.9,0.5,1.3,202,,109.5,294.5,19.3,,,4.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,8.3,,0.00%,,,,
24,0,China,Wuhan,48,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,All patients had high-sensitivity cardiac troponin I.,Kim,,12/25/2019,2/15/2020,52,Top-level,General,Positive and Negative/Unconfirmed,End-point and active,Both,Both,Yes,Both,All,NA,,70.58,13.38,,,,68.70%,,,,,,,,,,,,,,,66.70%,20.80%,27.10%,,,,,10.40%,14.60%,,,,70.80%,,,,,,,,,,,,,,,,,54.20%,45.80%,,6.485,4.145,8.825,122.92,,101.9,143.94,0,,,0.985,0.62,1.308,167,,116,217.5,,,,4.6,21,32,,43.2,,,,,,,,,,,,,,,,95.80%,97.90%,,,,,,45.80%,12.50%,60.40%,,37.50%,2.10%,,,,,,,,,,,,,,,,,,,,100%,,64.58%,,,,35.42%,35.42%,,,
24,1,China,Wuhan,17,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,,Kim,,12/25/2019,2/15/2020,52,Subgroup,Non-survivor,Positive and Negative/Unconfirmed,End-point only,Non-Survivors only,Both,Yes,Both,All,NA,,78.61,8.31,,,,70.60%,,,,,,,,,,,,,,,70.60%,29.40%,23.50%,,,,,29.40%,17.60%,,,,70.60%,,,,,,,,,,,,,,,,,23.50%,76.50%,,8.84,5.46,9.67,111.35,,87.39,135.31,0,,,0.92,0.51,1.29,119,,88.5,212.5,,,,3.9,19,33,,65.5,,,,,,,,,,,,,,,,100.00%,100.00%,,,,,,47.10%,23.50%,11.80%,,82.40%,5.90%,,,,,,,,,,,,,,,,,,,,100%,,0%,,,,100.00%,100.00%,,,
24,2,China,Wuhan,31,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,,Kim,,12/25/2019,2/15/2020,52,Subgroup,Survivor,Positive and Negative/Unconfirmed,End-point and active,Survivors only,Both,Yes,Both,All,NA,,66.16,13.66,,,,67.70%,,,,,,,,,,,,,,,64.50%,16.10%,29.00%,,,,,0.00%,12.90%,,,,71.00%,,,,,,,,,,,,,,,,,71.00%,29.00%,,5.74,4.14,7.39,29.26,,112.86,145.66,0,,,1.08,0.66,1.33,181,,146,220,,,,4.9,23,32,,23.8,,,,,,,,,,,,,,,,93.50%,96.80%,,,,,,45.20%,6.50%,87.10%,,12.90%,0.00%,,,,,,,,,,,,,,,,,,,,100%,,na,,,,0.00%,,,,
25,0,USA,Washington,21,Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State,JAMA,Arentz et al.,https://jamanetwork.com/journals/jama/fullarticle/2763485,English,,Kim,,2/20/2020,3/5/2020,14,Top-level,,Positive only,End-point and active,Both,Both,Yes,ICU only,All,NA,,70,,,,,52%,,,,,,,,,,,,,,86%,,33.30%,,,33.30%,,,47.60%,42.90%,,,,52%,37.6,39.2,48%,76%,,,,,,,,,,,,,,,,5.15,1.74,12.22,114,,80,137,1,,,0.889,0.2,2.39,215,,52,395,,,,,26.5,34,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.80%,19%,71%,,,,,,,,,,,,,14.30%,,,19.10%,19.10%,,,,100%,9.50%,,,,67.00%,87.58%,,,
26,0,Singapore,Singapore,18,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,"Small sample, lopinavir-ritonavir antivial medication went badly",Matthew,,1/23/2020,2/25/2020,33,Top-level,,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,47,,,31,73,0%,50%,100%,100%,,,,,,,,,,,,28%,28%,11%,,,,,,,,,,,72%,37.7,39.6,83%,11%,,,,,,17.00%,22.20%,,61%,,,,,,,4.6,1.7,6.3,13.5,,11.7,17.2,0,,,1.2,0.8,1.7,159,,116,217,,,,2.7,,,,16.3,,,,,,,,,,,,,,,,,27.78%,,,,,,,,,,6%,,,,,,,,,,,,,,,,,,,,,,11.10%,44.44%,0.33,,,0.00%,0.00%,,,
26,1,Singapore,Singapore,12,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,"Small sample, lopinavir-ritonavir antivial medication went badly",Matthew,,1/23/2020,2/25/2020,33,Subgroup,Did not require supplemental oxygen,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,37,,,31,56,0%,58%,100%,100%,,,,,,,,,,,,8%,8%,8.30%,,,,,,,,,,,58%,38.3,39.6,83%,8%,,,,,,25.00%,,,67.00%,,,,,,,4.6,1.7,6.3,13.9,,11.7,17.2,0,,,1.2,0.8,1.6,159,,128,213,,,,2.8,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,6%,,,,,,,,,,,,,,,,,,,,,,0.00%,41.67%,0,,,0.00%,0.00%,,,
26,2,Singapore,Singapore,6,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,"Small sample, lopinavir-ritonavir antivial medication went badly",Matthew,,1/23/2020,2/25/2020,33,Subgroup,Required supplemental oxygen,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,56,,,47,73,0%,33%,100%,100%,,,,,,,,,,,,67%,67%,16.70%,,,,,,,,,,,100%,37.3,38.1,83%,17%,,,,,,0.00%,,,50%,,,,,,,3.4,2.6,5.8,13.2,,11.7,14,0,,,1.1,0.8,1.7,156,,116,217,,,,1.8,,,,65.6,,,,,,,,,,,,,,,,,,,,,,,,,,,6%,,,,,,,,,,,,,,,,,,,,,,33.30%,50.00%,1,,,0.00%,0.00%,,,
27,0,Italy,Nationwide,355,Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy,JAMA,Onder et al.,https://jamanetwork.com/journals/jama/fullarticle/2763667?appId=scweb,English,Only case fatality rates by age (reporting on subsample with chart review),Ryan,,2/15/2020,3/17/2020,31,Top-level,Non-survivor,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,All,Both,80,79.5,,,,,70%,,,,,,,,,,,,,,98.20%,,35.50%,30%,,24.50%,20.30%,,,10%,,,,,,,,,,,,,,,,,,,,0%,100%,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,50%,0%,,,,100.00%,100.00%,,,
28,0,China,Wuhan,201,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,All patients,Ryan,Irra,12/25/2019,1/26/2020,32,Top-level,aggregate,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,51,,,43,60,,63.70%,49.30%,49.30%,,,,,,,,,,,,,19.40%,10.90%,4%,,2.50%,0.50%,,1%,7%,,,,93.50%,38.8,,81.10%,,,,32.30%,32.30%,,,,,,,,,,,,5.94,3.37,7.18,,,,,0,,,0.91,0.6,1.29,180,,137,241.5,,,,4.47,31,33,,48.1,6.98,,,,,,,353,236,,,,,,,97.50%,84.60%,,,,,,,,48.72%,,30.34%,2.51%,0.50%,,0.00%,,,,,,41.80%,,,,,,,,,,,100.00%,26.40%,71.64%,,13,,21.89%,23.40%,,,
28,1,China,Wuhan,84,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,Patients with ARDS,Ryan,Irra,12/25/2019,1/26/2020,32,Subgroup,with ARDS,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Ventilation only,58.5,,,50,69,,71.40%,,,,,,,,,,,,,,,27.40%,19%,6%,,,,,,,,,,92.90%,39,,81%,,,,32.10%,32.10%,,,,,,,,,,,,5.02,3.37,7.18,,,,,0,,,1.08,0.72,1.45,178,,140,239.5,,,,3.06,27,30,,23.4,6.29,,,,,,,371,234,,,,,,,98.80%,76.20%,,,,,,,,20.20%,,72.60%,6%,1.20%,,0%,,,,,,100%,,,,,,,,,,,100.00%,63.10%,16.67%,,,,52.38%,75.86%,,,
28,2,China,Wuhan,117,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,Patients without ARDS,Ryan,Irra,12/25/2019,1/26/2020,32,Subgroup,without ARDS,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Non-ventilation only,48,,,40,54,,58.10%,,,,,,,,,,,,,,,13.70%,5.10%,2.60%,,,,,,,,,,94.00%,38.6,,82.20%,,,,32.50%,32.50%,,,,,,,,,,,,8.32,5.07,11.2,,,,,0,,,0.67,0.49,0.99,187,,124.5,252.5,,,,7.04,35,38,,83,7.39,,,,,,,241,157.5,,,,,,,96.60%,90.60%,,,,,,,,69.20%,,0%,0%,0%,,0%,,,,,,0%,,,,,,,,,,,100%,0%,100%,,,,0.00%,0.00%,,,
30,1,China,Xi'an,17,"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial",medRxiv,Bien et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,English,"Does not report mortality, but has data over time",Agni,,2/3/2020,2/10/2020,7,Subgroup,meplazumab,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,51,,,49,67,,64.70%,,58.80%,5.90%,,,,,,,,,5.90%,,52.90%,35.30%,17.60%,5.90%,,5.90%,,,,,41.20%,,,94.10%,,37.7,52.90%,58.80%,,5.90%,58.80%,58.80%,,11.80%,,,,,,,23.50%,35.30%,41.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,94.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,76.47%,,,,,,,,
30,2,China,Xi'an,11,"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial",medRxiv,Bien et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,English,"Does not report mortality, but has data over time",Agni,,2/3/2020,2/10/2020,7,Subgroup,no meplazumab,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,64,,,43,67,,45.50%,,36.40%,18.20%,,,,,,,,,9.10%,,36.40%,27.30%,0%,18.20%,,0,,,,,45.50%,,,100%,,37.7,63.60%,63.60%,,18.20%,45.50%,45.50%,,9.10%,,,,,,,36.40%,36.40%,27.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,90.90%,100%,,,,,,63.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,36.36%,,,,,,,,
31,0,China and outside China,,507,Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population- level observational study,Lancet,Sun et al.,https://www.thelancet.com/action/showPdf?pii=S2589-7500%2820%2930026-1,English,data available here: https://docs.google.com/spreadsheets/d/1Gb5cyg0fjUtsqh3hl_L-C5A23zIOXmWH5veBklfSHzg/edit#gid=447265963,Yuchen,Irra,1/20/2020,1/31/2020,11,Top-level,,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,46,,35,60,,55%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,7.89%,,,,
32,0,China,Beijing,262,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,,Agni,Irra,1/20/2020,2/10/2020,21,Top-level,All cases,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,47.5,,,,,,48.50%,92%,40.50%,49.20%,,6.7,,,,,,,,,,,,,,,,,,,,,,82.10%,,37.7,45.80%,6.90%,6.50%,,,26.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,81.70%,,17.20%,,,,0.90%,4.97%,,,
32,1,China,Beijing,46,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,,Agni,,1/20/2020,2/10/2020,21,Subgroup,severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,61.4,,,,,,56.50%,89.10%,28.30%,56.50%,,7.5,,,,,,,,,,,,,,,,,,,,,,80.40%,,37.7,54.30%,32.60%,6.50%,,,32.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.10%,,4.30%,,,,6.50%,60.19%,,,
34,0,China,Wuhan,5,Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation,Journal of Infection,Ye et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301146,English,Not relevant now (only repeat cases). Individual patient level,EXCLUDE,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
32,2,China,Beijing,216,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,"contains 192 mild cases, 11 non-pneumonia cases, 13 asymptomatic cases",Agni,,1/20/2020,2/10/2020,21,Subgroup,common,Positive only,End-point and active,Survivors only,Both,No,ΝΑ,Mild only,NA,44.5,,,,,,46.80%,92.60%,43.10%,47.70%,,6.5,,,,,,,,,,,,,,,,,,,,,,82.40%,,37.7,44.00%,1.40%,6.50%,,,25.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,80.10%,,19.90%,,,,0.00%,0.00%,,,
33,0,China,Wuhan,9,Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records,Lancet,Chen et al.,https://www.sciencedirect.com/science/article/pii/S0140673620303603,English,"Not applicable for now specific to pregnant women (probably too specific for now) - isolated data per patient, could be useful if we decide to create a dataset with personalized information",EXCLUDE,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
35,1,China,Anhui,6,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,"given ""appropriate treatment"" (unspecified), include CT findings",Holly,,1/21/2020,2/3/2020,13,Subgroup,Mild,Positive only,End-point and active,,Both,Yes,,Mild only,,,29.2,10.9,,,,50%,,67%,33%,,,,,,,,,,,,,,,,,,,,,,,,83%,,,67%,,0%,17%,,67%,,,,0,11%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
35,2,China,Anhui,43,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,"given ""appropriate treatment"" (unspecified), include CT findings",Holly,,1/21/2020,2/3/2020,13,Subgroup,Common,Positive only,End-point and active,,Both,Yes,,Mild only,,,33.4,12.2,,,,65%,,67%,28%,,,,,,,,,,,,,,,,,,,,,,,,93%,,,84%,,11%,51%,,72%,,,,19%,7%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
35,3,China,Anhui,21,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,"given ""appropriate treatment"" (unspecified), include CT findings",Holly,,1/21/2020,2/3/2020,13,Subgroup,Severe,Positive only,End-point and active,,Both,Yes,,Severe/Critical Only,,,44.2,12,,,,48%,,85%,10%,,,,,,,,,,,,,,,,,,,,,,,,95%,,,86%,,10%,67%,,81%,,,,43%,10%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
35,4,China,Anhui,3,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,"given ""appropriate treatment"" (unspecified), include CT findings",Holly,,1/21/2020,2/3/2020,13,Subgroup,Critical,Positive only,End-point and active,,Both,Yes,,Severe/Critical Only,,,63,21.2,,,,0%,,100%,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,67%,,33%,67%,,100%,,,,100%,0%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
36,1,China,Shenzhen,35,Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study,Engineering,Cai et al.,https://www.sciencedirect.com/science/article/pii/S2095809920300631,English,"treatment study; only improve/decline, changed from End-point only to End-point and active because Viral clearance was assumed to be cured, and it did not appear everyone was",Holly,,1/24/2020,2/14/2020,21,Subgroup,FPV,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,All,Non-ventilation only,43,,,35.5,59,,40.00%,57.10%,57.10%,,,,,,,,,,,,,,,,,,,,,,,,,62.90%,,,34.30%,,8.60%,,,,,2.90%,,,17.10%,0%,,,,,,8.1,3.8,6.6,,,,,1,,,1.5,1,1.8,,,,,,,,3,21.6,24.1,26.9,15,14,,,,,,,593.3,397.8,,,,,,,,100%,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,4.00,0.00%,,91.43%,6.45%,3.23%
36,2,China,Shenzhen,45,Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study,Engineering,Cai et al.,https://www.sciencedirect.com/science/article/pii/S2095809920300631,English,treatment study; only improve/decline,Holly,,1/24/2020,2/14/2020,21,Subgroup,LPV/RTV,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,All,Non-ventilation only,49,,,36,61,,46.70%,57.80%,57.80%,,,,,,,,,,,,,,,,,,,,,,,,,82.20%,,,22.20%,,11.10%,,,,,0%,,,4.40%,2.20%,,,,,,4.3,3.4,4.9,,,,,1,,,1.2,0.9,1.4,,,,,,,,2.6,22.6,25.8,24.4,21.4,12.9,,,,,,,542.3,326.4,,,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,11.00,0.00%,,62.22%,17.78%,20.00%
37,1,China,Beijing,9,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,include CT findings,Holly,,1/1/2020,2/21/2020,51,Subgroup,Mild,Positive only,Active only,Both,Both,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,78%,,89%,11%,,,,,,,,,,,,,,,,,,,,,,,,67%,,,33%,,,11%,0%,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
37,2,China,Beijing,28,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,include CT findings,Holly,,1/1/2020,2/21/2020,51,Subgroup,Moderate,Positive only,Active only,Both,Both,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,54%,,57%,39%,,,,,,,,,,,,,,,,,,,,,,,,96%,,,39%,,,14%,14%,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
37,3,China,Beijing,10,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,include CT findings,Holly,,1/1/2020,2/21/2020,51,Subgroup,Severe,Positive only,Active only,Both,Both,No,Non-ICU only,Severe/Critical Only,Non-ventilation only,,,,,,,70%,,60%,40%,,,,,,,,,,,,,,,,,,,,,,,,80%,,,40%,,,10%,30%,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
37,4,China,Beijing,3,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,include CT findings,Holly,,1/1/2020,2/21/2020,51,Subgroup,Critically Severe,Positive only,Active only,Both,Both,No,ICU only,Severe/Critical Only,Both,,,,,,,0%,,0%,67%,,,,,,,,,,,,,,,,,,,,,,,,67%,,,67%,,,33%,33%,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.00%,,,,
38,0,China,Shanghai,249,"Clinical progression of patients with COVID-19 in Shanghai, China",Journal of Infection,Chen et al. ,https://www.sciencedirect.com/science/article/pii/S0163445320301195,English,no subgroups; doesn't discuss treatments,Ryan,Irra,1/20/2020,2/6/2020,17,Top-level,All,Positive only,End-point and active,Both,Both,No,Both,All,NA,51,51,,36,64,,50.60%,,,,,,,,4,4,2,7,,,36.10%,21.70%,,,,,0.40%,,,16.40%,,,,87.10%,,,36.50%,7.60%,11.20%,,,15.70%,,3.20%,,3.20%,6.40%,,,2.80%,10%,5%,5%,4.71,3.8,5.86,,,,,1,,12,1.12,0.79,1.49,,,,,,,,,23,25,,12,,,,,,,,431,256.54,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.20%,,,,,,,,,,,,8.80%,86.30%,,16,,0.80%,0.92%,,,
39,1,China,Zhejiang,72,"Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings",Intl Journal of Infectious Disease,Zhang et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301727,English,non-intesive and intensive ventilation reported together.,Kim,Irra,1/17/2020,2/8/2020,22,Subgroup,Normal Imaging Findings,Positive only,Active only,Both,Both,Yes,ΝΑ,All,NA,,34.9,14.2,,,,45.80%,,91.70%,8.30%,,,,,,,,,,,16.70%,5.60%,5.60%,0%,,0%,0%,,0%,4.20%,,,,66.70%,,,45.80%,0,2.80%,23.60%,7%,12.50%,,11.10%,,,23.60%,,,,,,,5.42,3.42,7.42,141.04,,125.42,156.66,1,,,1.39,0.78,2,198.44,,140,256.88,9.11,4.25,13.97,3.48,25.53,26.67,,2.3,,,,,,,,,,,,,,,,,77.80%,,,,,,,,11.10%,,0,0,0%,0%,0%,,,,,,0%,,,,8.30%,,,0%,,,,,0%,na,,,,,,,,
39,2,China,Zhejiang,573,"Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings",Intl Journal of Infectious Disease,Zhang et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301727,English,include imaging findings,Kim,,1/17/2020,2/8/2020,22,Subgroup,Abnormal Imaging Findings,Positive only,Active only,Both,Both,Yes,ΝΑ,All,NA,,46.65,13.82,,,,51.50%,,81.00%,19%,,,,,,,,,,,28.80%,16.80%,7.70%,1%,,0%,1%,,1%,6.50%,,,,85.90%,,,68.40%,4.50%,11.30%,36%,11.50%,19%,,7.90%,,,14%,,,,,,,5.01,3.14,6.88,138.09,,121.62,154.56,1,,,1.23,0.71,1.75,185.22,,122.8,247.64,11.26,3.22,19.3,3.29,29.37,30.08,,8.8,,,,,,,,,,,,,,,,,85.20%,,,,,,,,43.60%,,1.60%,1.60%,0%,13.40%,0%,,,,,,2.40%,,,,13.10%,,,0.30%,,,,,0.70%,na,,,,,,,,
40,1,China,Changzhou,15,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,Intl Journal of Innfectious Diseases,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,English,"breakdown by contact (direct vs. secondary, tertiary transmission)",Kim,,1/23/2020,2/18/2020,26,Subgroup,Imported contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,35,,,29,51,,66.70%,,,,,8,4,10,,,,,,,0%,,0%,0%,,0%,,,0%,0%,,,,73.30%,,,33.30%,13.30%,,20%,26.70%,6.70%,,13.30%,,,,,,,100%,,,5.2,4.6,6.3,,,,,0,,,1.5,0.9,2.1,,,,,,,,,22.9,19,,4.4,,,,,,,,399,287,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,,
40,2,China,Changzhou,17,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,,,Kim,,1/23/2020,2/18/2020,26,Subgroup,Secondary contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,37,,,24,47.5,,41.20%,,,,,8,4,11,,,,,,,23.50%,,5.90%,11.80%,,0%,,,5.90%,0%,,,,58.80%,,,52.90%,5.90%,,35.30%,11.80%,0%,,5.90%,,,,,,,100%,,,4.8,3.4,6.2,,,,,0,,,1.1,1,1.9,,,,,,,,,13.5,17,,2.2,,,,,,,,375,267,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,,
40,3,China,Changzhou,19,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,,,Kim,,1/23/2020,2/18/2020,26,Subgroup,Terciary contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,53,,,35,65,,42.10%,,,,,12,9,14,,,,,,,42.10%,,15.80%,15.80%,,5.30%,,,0%,5.30%,,,,68.40%,,,47.40%,5.30%,,21.10%,10.50%,10.50%,,10.50%,,,,,,,100%,,,3.9,3.1,5.7,,,,,0,,,1.3,0.9,1.6,,,,,,,,,25.2,22,,7,,,,,,,,374,303,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,,
41,0,China,Xiaogan,114,Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area,COVID-19) in the Xiaogan area,Wang et al.,https://www.sciencedirect.com/science/article/pii/S000992602030088X,English,include CT findings but not outcomes/treatment received,Agni,Irra,1/25/2020,2/9/2020,15,Top-level,All,Positive only,Active only,Both,Both,No,ΝΑ,Mild only,NA,53,,,23,78,,50.90%,78.90%,,,,,,,,,,,,,52.60%,28.90%,13.20%,6.10%,,4.40%,0.90%,,,5.30%,,,,93.90%,,38.6,79.80%,23.70%,,7.90%,,,,2.70%,,,5.30%,,,,100.00%,0.00%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,,
42,0,China,Shandong,537,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,Yuchen,Irra,1/19/2020,2/15/2020,27,Top-level,,Positive only,End-point and active,Both,Both,Yes,Both,All,,,,,,,,55.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,87.90%,,,35.90%,,,,,8.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.40%,,,,
42,1,China,Shandong,509,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,Irra,Irra,1/19/2020,2/15/2020,27,Subgroup,Common,Positive only,End-point and active,Both,Both,Yes,Both,Mild only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,31.54%,,,,,,,,
42,2,China,Shandong,16,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,Irra,Irra,1/19/2020,2/15/2020,27,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,,,,,,,,62.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,68.80%,98.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,3,China,Shandong,12,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,Irra,Irra,1/19/2020,2/15/2020,27,Subgroup,Critical,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,,,,,,,,41.67%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
43,0,China,Hubei,49,湖北省十堰市新型冠状病毒肺炎 49 例临床分析,第三军医大学学报,赵琴，雷旭，刘龙，占国清，李儒贵，李金科，李芳，杜卫星，李健，杨靖， 谭华炳,DOI：10.16016/j.1000-5404.202002107,Chinese,,Yuchen,Irra,1/23/2020,2/9/2020,17,Top-level,,Positive only,,,,,,,,48,,,,,,51.02%,,91.80%,,,,,,,,,,,,36.73%,,,,,,,,,,,,,87.76%,,,65.31%,12.24%,24.49%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,0,China,Hubei,463,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,Yuchen,Irra,1/1/2020,2/6/2020,36,Top-level,survival,Positive only,Active only,Survivors only,Discharged only,Yes,Both,All,,51,,,,,,52.70%,,,,,9,7,12.5,,,,,,,44.28%,23.11%,8.64%,6.05%,,,,,,,,,,89.63%,38.5,40.5,77.06%,41.90%,13.17%,31.53%,,28.08%,,,,,,,,,,,,5.44,4.09,7.52,126,,114,126,,,,1.07,0.76,1.46,212,,155,285,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12,,0.00%,,,,
44,1,China,Hubei,282,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,Irra,Irra,1/1/2020,2/6/2020,36,Subgroup,Common,Positive only,Active only,Survivors only,Discharged only,Yes,Both,Mild only,,49,,,42,58,,51.42%,,,,,10,7,13,,,,,,,40.43%,19.15%,7.09%,4.26%,,,,,,,,,,86.88%,38.4,,74.82%,39.72%,5.32%,29.08%,,28.72%,,,,,,,,,,,,5.17,4.08,,6.71,,115,138,,,,1.18,0.87,1.61,214,,165,285,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11,,0.00%,,,,
44,2,China,Hubei,181,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,Irra,Irra,1/1/2020,2/6/2020,36,Subgroup,Severe,Positive only,Active only,Survivors only,Discharged only,Yes,Both,Severe/Critical Only,,54,,,46,64,,54.70%,,,,,8,7,12,,,,,,,50.28%,29.28%,11.05%,8.84%,,,,,,,,,,93.92%,38.9,,80.11%,45.30%,5.52%,35.36%,,27.07%,,,,,,,,,,,,5.92,4.13,,8.26,,107,136,,,,0.95,0.63,1.3,204,,142,275,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13,,0.00%,,,,
45,0,China,,76,76例新型冠状病毒肺炎患者的临床及CT影像特征分析,中医杂志,陈甜，蒋宗焰，许炜，张清,,Chinese,,Yuchen,,,,0,Subgroup,,Positive only,End-point and active,,,Yes,ICU only,All,,62,,,,,,55.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,75%,,,67.11%,18.42%,,,,38.16%,,,,,6.58%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.94%,,,,
46,0,China,Henan,524,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,Yuchen,Irra,2/1/2020,2/20/2020,19,Top-level,,Positive only,,,,Yes,,All,,45,,,33,55,,58.00%,,54.80%,62.20%,,10,6,15,,,,,,,,,,,,,,,,,,,,47.30%,,,12.79%,26.34%,5.53%,11.07%,5.15%,31.30%,,2.67%,4.20%,,16.79%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,1,China,Henan,,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,,Irra,2/2/2020,2/21/2020,19,Subgroup,Common,Positive only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,2,China,Henan,,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,,Irra,2/3/2020,2/22/2020,19,Subgroup,Severe,Positive only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,3,China,Henan,,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,,Irra,2/4/2020,2/23/2020,19,Subgroup,Critical,Positive only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,0,China,Chongqing,223,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,Irra,,1/24/2020,2/23/2020,30,Top-level,All,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,Both,,46.5,,30.4,62.6,,47.10%,,28.70%,34.10%,,,,,5,,,,15.70%,,24.20%,11.20%,8.10%,0.40%,,0.40%,,,,4%,3.10%,,,53.40%,,,50.70%,6.70%,4.90%,12.10%,5.40%,5.40%,,5.40%,,,,,,,,,,,,,135.1,,,,,,69.4,1.5,,,199.8,,,,18.8,,,,20,30,,,,,,,,,,,,,,,,,,,100%,,,,,,,,58.30%,,5.40%,1.30%,,7.60%,,,,,,,,,,,,,,,,,,,,50.20%,,14,11.9,0.00%,0.00%,,,
47,1,China,Chongqing,223,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,Irra,,1/24/2020,2/23/2020,30,Subgroup,Common,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,Both,,44.9,,28.9,60.9,,45.30%,,27.60%,37.50%,,,,,4,,,,15.60%,,20.80%,10.90%,5.20%,0.50%,,0.50%,,,,3.60%,1.00%,,,47.90%,,,49.50%,0,5.20%,10.40%,5.20%,5.20%,,6.30%,,,,,,,,,,,,,135.9,,,,,,69.5,1.5,,,197.8,,,,19.2,,,,20,26,,,,,,,,,,,,,,,,,,,100%,,,,,,,,63.50%,,0,0,,9%,,,,,,,,,,,,,,,,,,,,52.60%,,13.8,11.7,0.00%,0.00%,,,
47,2,China,Chongqing,223,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,Irra,,1/24/2020,2/23/2020,30,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,Both,,56.4,,44,68.8,,58.10%,,35.50%,12.90%,,,,,6,,,,16.10%,,45.20%,12.90%,25.80%,0,,0,,,,6.50%,16.10%,,,87.10%,,,58.10%,48.40%,3.20%,22.60%,6.50%,6.50%,,0,,,,,,,,,,,,,130.1,,,,,,68.2,1,,,211.8,,,,17.5,,,,34,60,,,,,,,,,,,,,,,,,,,100%,,,,,,,,25.80%,,38.70%,9.70%,,54.80%,,,,,,,,,,,,,,,,,,,,35.50%,,16.4,13.9,0.00%,0.00%,,,
48,0,China,Jiangxi,49,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,1/21/2020,1/27/2020,6,Top-level,All,Positive only,,,,,,All,,,42.9,,,,,67.32%,93.89%,,,4.7,,,,6.7,,,,6.12%,,28.60%,12.20%,4.10%,,,,,,,12.20%,,,,78.70%,37.1,39.1,38.80%,,12.20%,,,18.40%,,4.10%,,,14.90%,16.30%,,,81.63%,,,5.52,,,,,,,,,,,,,,,,,,,,3.84,22.7,27.4,,27.77,,,,,,,,312.16,174.74,,,,,,,,15.38%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,1,China,Jiangxi,40,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,1/21/2020,1/27/2020,6,Subgroup,Common,Positive only,,,,,,Mild only,,,40.6,,,,,62.50%,97.50%,,,4.7,,,,,,,,7.50%,,,5.00%,0,,,,,,,15%,,,,80.00%,37.2,,32.50%,,10.00%,7.50%,,15.00%,,5.00%,,,17.50%,12.50%,,,,,,4.61,,,,,,,,,,,,,,,,,,,,2.96,20.7,25.1,,16.05,,,,,,,,352.75,201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,2,China,Jiangxi,9,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,Zhen,Irra,1/21/2020,1/27/2020,6,Subgroup,Severe/Critical,Positive only,,,,,,Severe/Critical Only,,,53,,,,,88.90%,77.78%,,,4.5,,,,,,,,0,,,44.44%,22.22%,,,,,,,,,,,66.67%,36.9,,66.67%,,22.22%,44.44%,,33.33%,,0,,,0,33.33%,,,,,,9.56,,,,,,,,,,,,,,,,,,,,7.76,32,38.1,,79.86,,,,,,,,221.32,145.35,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,,China,Hubei,41,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,EXCLUDE,Irra,,1/24/2020,43854,,reference data from another paper,Positive only,,,,,Both,All,,49,,,,,,73.00%,,,,,,,,,,,,,,32.00%,,,,,,,,,,,,,98.00%,,,76.00%,,,,44%,44%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,,China,Hubei,99,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,EXCLUDE,Irra,,1/30/2020,43860,,reference data from another paper,Positive only,,,,,,,,,55.5,,,,,,,,,,,,,,,,,,,51.00%,,,,,,,,,,,,,83.00%,,,82.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,,China,Hubei,138,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,EXCLUDE,Irra,,,0,,reference data from another paper,Positive only,,,,,Both,,,56,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,98.60%,,,59.40%,,,,,69.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26.10%,,,,,,,,,
49,0,China,,26,26例新型冠状病毒肺炎确诊病例临床和流行病学特征,中华医院感染学杂志,"庄英杰,陈竹,李进,杨兴龙,李靖,袁月,管群,贾红军,马婧怡,吴丹,马洪滨,汤紫荣",,Chinese,,Zhen,Irra,2020/01/??,before 02/12/2020,#VALUE!,Top-level,,Positive only,,,,,,,,,39.77,,,,,76.50%,,53.85%,46.15%,,,,,,,,,,,42.30%,15.38%,11.54%,,,,,,,15.38%,,,,76.92%,,,30.77%,,23.08%,11.54%,26.92%,53.85%,,11.54%,,,15.38%,11.54%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
50,0,China,,308,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/2020,2/20/2020,26,Top-level,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,,,52.95324675,,38.73733766,,,47.81%,,,,,,,,,,,,,,,,,,,,,,,,,,,82.00%,,,95.00%,,,,,67.90%,,10.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.21626328,,5.19%,,,,
50,1,China,,34,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/2020,2/20/2020,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,,,65.1,,51.8,78.4,,54.54%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.40909091,,36.36%,,,,
50,2,China,,87,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/2020,2/20/2020,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,,,58.4,,43.1,73.7,,54.02%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,95.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19.43103448,,4.60%,,,,
50,3,China,,98,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/2020,2/20/2020,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,,,45.8,,31.9,59.7,,43.88%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,99.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16.4,,0.00%,,,,
50,4,China,,90,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,Irra,Irra,1/25/2020,2/20/2020,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,,,50.3,,36.6,64,,43%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,94.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.7,,0.00%,,,,
51,0,China,Hunan,697,湖南省 697 例新型冠状病毒肺炎确诊病例就诊及诊断分析,实用预防医学,刘子言，高立冬，胡世雄，罗垲炜，肖洁华，赵善露，曾舸，戴志辉，杨浩， 孙倩莱，张恒娇，邓志红,,Chinese,"No Treatment or Outcome, Can discard",Michael,Irra,12/21/2019,2/13/2020,54,Top-level,,Positive only,Active only,Both,Both,No,Both,All,Both,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
52,0,China,Meta-study (might be possible to extract more data by looking at references in paper),"44,672",新型冠状病毒肺炎流行病学特征分析,中华流行病学杂志,中国疾病预防控制中心新冠状病毒肺炎应急响应机制流行病学组,http://html.rhhz.net/zhlxbx/004.htm,Chinese,EXCLUDE,EXCLUDE,Irra,12/31/2019,2/11/2020,42,Top-level,,Positive only,Active only,Both,Both,No,Both,All,Both,,50.92,,35,75,3.80%,51.40%,,85.20%,,,,,,,,,,,,26%,12.80%,5.30%,4.20%,,2.40%,0.50%,,,,,,,,,,,,,,,,,,,,,,,,80.90%,13.80%,4.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.30%,,,,
53,0,China,Guangdong,188,Evidence and characteristics of human-to-human transmission of 2019-nCoV,MedRxiv,Kang et. al.,https://www.medrxiv.org/content/medrxiv/early/2020/02/06/2020.02.03.20019141.full.pdf,English,Patient level data in supplementary materials,Sam,,1/1/2020,1/27/2020,26,Top-level,All,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,48.8,,,,,49.50%,,75%,,5.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,84.50%,12.20%,3.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,,
54,0,China,Various,9,Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China,JAMA,Wei et. al.,https://doi.org/10.1001/jama.2020.2131,English,"Only <1yr old, minimal data",Holly,,12/8/2019,2/6/2020,60,Top-level,All,Positive only,End-point and active,Survivors only,,No,Non-ICU only,Mild only,Non-ventilation only,0.58,0.56,,0.33,0.75,,22%,87.50%,,,,,,,,,,,,,,,,,,,,,,,,,,44%,,,22%,,,11%,,,,,,,11%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,,
55,0,China,Wuhan,1,A new coronavirus associated with human respiratory disease in China,Nature,Fan et. al,https://www.nature.com/articles/s41586-020-2008-3?fbclid=IwAR10YjXQeW795Vke_56S0Qz-eZzCXSosAAYpF6vuWjWH8vnGIUKWJr1BkoI,English,One patient (see Table 1); only use if we get desperate,Holly,,12/26/2019,1/7/2020,12,Top-level,All,Positive only,Active only,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,41,41,,,,,100%,100%,100%,,,,,,6,,,,,,,,,,,,,,,,,,,100%,,38.4,100%,100%,,100%,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,4.1,,,,,,,,,,,,,,,,100%,100%,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,100%,na,3,,,,,,,
56,0,China,Wuhan,10,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,Can split by survivors/non survivors,Agni,,1/1/2020,2/11/2020,41,Top-level,All,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.3,3.5,5.1,138,,121,151,0,,,0.7,0.6,0.9,165,,135,219,,,,2.8,24,26,,12.1,17,,,,,,,,,,,,,,,100%,60%,60%,,,,,50%,,,100%,,,,,,,,,,,,,,,,,,,,,,,,60%,,,,20.00%,25.00%,,,
56,1,China,Wuhan,8,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,,Agni,,1/1/2020,2/11/2020,41,Subgroup,Survivors,Positive only,End-point and active,Survivors only,Both,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.2,3.2,5,138,,126,150,0,,,0.8,0.7,0.9,167,,150,221,,,,2.6,21,23,,10.1,13,,,,,,,,,,,,,,,100%,,75%,,,,,37.50%,,,100%,,,,,,,,,,,,,,,,,,,,,,,,75%,,,,0.00%,0.00%,,,
56,2,China,Wuhan,2,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,,Agni,,1/1/2020,2/11/2020,41,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.6,3.5,5.7,137,,128,146,0,,,0.7,0.6,0.8,170,,121,219,,,,4.3,28,30,,25.5,21,,,,,,,,,,,,,,,100%,,0%,,,,,100%,,,100%,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,100.00%,100.00%,,,
57,0,China,Guizhou,162,"Epidemiologic Characteristics of COVID-19 in Guizhou, China",MedRxiv,Ping et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20028944v1.full.pdf,English,"No treatment or outcomes, and features very sparse. Recommend dropping",Ted,,1/21/2020,2/16/2020,26,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,37,,,,,,50.62%,91.35%,51.85%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,,
58,0,China,Shanghai,148,Clinical Features of COVID-19-Related Liver Damage,Lancet,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,Split by liver functions,Ted,,1/20/2020,1/31/2020,11,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,50.5,,,36,64,,49.30%,,,,,,,,,5,3,7,,,,,,,,,,,,,,,,70.30%,,,45.30%,,,26.70%,,,,4.10%,2%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16%,39.20%,21%,,,,,,,,,,,,,,,,,,,,,,,44.60%,,,,,,,,,62.84%,,12,,0.68%,1.07%,,,
58,1,China,Shanghai,75,Clinical Features of COVID-19-Related Liver Damage,Lancet,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,,Ted,,1/20/2020,1/31/2020,11,Subgroup,Abnormal liver,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,62.67%,,,,,,,,,,,,,,,,,,,,,,,,,,,76%,,,46.67%,,,22.67%,,,,,,,,,,,,,,4.99,,,,,,,,,,0.925,0.635,1.734,,,,,,,,,,,,,,,,,,,,336,201,,,,,,,22.67%,45.33%,31.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,59%,,15.14,,,,,,
58,2,China,Shanghai,73,Clinical Features of COVID-19-Related Liver Damage,Lancet,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,,Ted,,1/20/2020,1/31/2020,11,Subgroup,Normal liver,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,38.36%,,,,,,,,,,,,,,,,,,,,,,,,,,,64%,,,43.84%,,,27.34%,,,,,,,,,,,,,,4.3,,,,,,,,,,1.32,1.734,1.57,,,,,,,,,,,,,,,,,,,,492,273,,,,,,,9.59%,32.88%,11%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,81%,,12.67,,,,,,
59,0,China,Wuhan,82,Clinical characteristics of 82 death cases with COVID-19,MedRxiv,Zhang et. al.,https://www.medrxiv.org/content/10.1101/2020.02.26.20028191v1.full.pdf,English,,Agni,,1/11/2020,2/10/2020,30,Top-level,Only non-survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,Both,Severe/Critical Only,Both,72.5,,,65,80,,65.90%,,,,,7,4,10,,,,,,,76.80%,56.10%,18.30%,20.70%,,14.60%,7.30%,,7.30%,12.20%,,,,78%,38.8,,64.60%,63.40%,,,,46.30%,,12.20%,2.30%,,4.90%,,,,,,100%,,,,,,,,,,,0.5,0.3,0.8,148.5,,102,206,13.6,10,22.9,6.8,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,35.30%,,,100%,36.60%,4.80%,,,,,,28%,,100%,,,24.60%,,,,,,,,,100%,17.10%,0%,,5,,100.00%,100.00%,,,100%
60,0,China,Jiangxi,11,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,Can split by naive/experienced,Matthew,,2/12/2020,3/19/2020,36,Top-level,All Survive,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,,,,,,,36.40%,18.20%,,9.10%,,,,,,,,,,,18.20%,18.20%,,,,,,,,,,,,36.40%,,,36.40%,63.60%,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,100%,,17.81,,0.00%,0.00%,,,
60,1,China,Jiangxi,2,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,Naive had no prior drugs,Matthew,,2/12/2020,3/19/2020,36,Subgroup,Naive,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,31,,,18,44,,50.00%,50.00%,,,,,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,0.00%,,,50.00%,50.00%,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,100%,,8,,0.00%,0.00%,,,
60,2,China,Jiangxi,9,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,Prior antiviral therapy,Matthew,,2/12/2020,3/19/2020,36,Subgroup,Experienced,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,44,,,18,66,,33.30%,11.10%,,11.10%,,,,,,,,,,,22.20%,22.20%,,,,,,,,,,,,44.40%,,,33.30%,66.60%,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,100%,,20,,0.00%,0.00%,,,
61,1,China,Two provinces,163,A comparative multi­center study on the clinical and imaging features of confirmed and unconfirmed patients with COVID­19,MedRxiv,Miao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040782v1.full.pdf,English,This study provides results for unconfirmed and confirmed; I would just report on confirmed,Léonard,,1/12/2020,2/13/2020,32,Subgroup,Confirmed,Positive only,Active only,Survivors only,Non-discharged only,Yes,Both,All,Both,43.8,,,,,,51.60%,,71%,38.60%,7,,,,,,,,24.8%,16.80%,,13.90%,5%,2%,,3%,1%,,0%,,,,,79%,,,59.70%,4.80%,8.10%,16.10%,24.20%,24.20%,4.80%,11.30%,,,8.10%,,,4.80%,,,6.50%,5.3,4,6.7,138.8,,122.1,155.5,1,,,1.3,0.9,1.8,178,,130.5,215.5,9.7,7.4,13.1,2.9,22,25.5,,9.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,0.00%,,,,
62,0,China,Chongqing,167,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,Can split by both severity and age (tables 2-3 report results for severe and asymptomatic by age),Arthur,,1/1/2020,3/1/2020,60,Top-level,,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,,,32.20%,49.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,74.80%,13.10%,0%,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,16.68,,0.00%,0.00%,,,
62,1,China,Chongqing,2,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Asymptomatic 0-14,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,0.00%,100.00%,9,,,,,,,,0.00%,,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,100.00%,0.00%,0%,0%,4.66,3.81,5.5,,,,,0,,,2.925,1.91,3.94,140.5,,30,251,,,,,,,,,,,,,,,,811,561,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,,,100%,,16.5,,0.00%,0.00%,,,
62,2,China,Chongqing,2,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Asymptomatic 15-29,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,50.00%,50.00%,8.5,,,,,,,,0.00%,,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,100.00%,0.00%,0%,0%,3.9,,,,,,,0,,,1.63,1.21,2.05,166,,,,,,,46.80%,,,,,,,,,,,,691,537,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,,,100%,,10.5,,0.00%,0.00%,,,
62,3,China,Chongqing,2,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Asymptomatic 30-39,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,50.00%,0.00%,20.5,,,,,,,,50.00%,,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,100.00%,0.00%,0%,0%,7.105,5.11,9.1,,,,,0,,,2.135,1.31,2.96,229,,221,237,,,,62.15%,,,,,,,,,,,,420,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,,,100%,,16,,0.00%,0.00%,,,
62,4,China,Chongqing,6,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Asymptomatic 40-49,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,0.00%,66.70%,8.8,,,,,,,,33.30%,,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,100.00%,0.00%,0%,0%,5.9,4.11,6.27,,,,,0,,,1.3,0.96,1.99,183,,87,328,,,,63.00%,,,,,,,,,,,,433,370,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,16.70%,,0.00%,,,0,,,,,,100%,,12.2,,0.00%,0.00%,,,
62,5,China,Chongqing,5,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Asymptomatic 50-59,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,0.00%,80.00%,7,,,,,,,,40.00%,,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,100.00%,0.00%,0%,0%,6.42,6.68,9.4,,,,,0,,,2.04,2.03,3,197,,192,198,,,,62.50%,,,,,,,,,,,,253,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,,,100%,,11.6,,0.00%,0.00%,,,
62,6,China,Chongqing,3,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Asymptomatic 70+,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,,0.00%,100.00%,13.7,,,,,,,,0.00%,,,,,,,,,,,,,,,0%,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,100.00%,0.00%,0%,0%,5.19,5.17,8.05,,,,,0,,,0.83,0.78,2.57,,,,,,,,69.20%,,,,,,,,,,,,273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,,,100%,,19,,0.00%,0.00%,,,
62,7,China,Chongqing,7,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Severe 30-39,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,71.40%,28.60%,9.1,,,,,,,,28.60%,,,,,,,,,,,,,,,100%,,,71.40%,14.30%,57.10%,,,57.10%,,,,,,,,0.00%,0.00%,100%,0%,5.29,4.1,8.2,,,,,0,,,2.19,0.67,2.97,205.5,,133,503,,,,60.30%,,,,,,,,,,,,399,342,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,14.30%,,,0,,,,,,100%,,18.3,,0.00%,0.00%,,,
62,8,China,Chongqing,3,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Severe 40-49,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,66.70%,33.30%,8.3,,,,,,,,0.00%,,,,,,,,,,,,,,,66.70%,,,66.70%,33.30%,0,,,0%,,,,,,,,0.00%,0.00%,100%,0%,3.3,3.26,3.34,,,,,0,,,0.855,0.75,0.96,186,,174,233,,,,60.70%,,,,,,,,,,,,393,304,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0,,,0,,,,,,100%,,17,,0.00%,0.00%,,,
62,9,China,Chongqing,5,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Severe 50-59,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,80.00%,20.00%,12.3,,,,,,,,20%,,,,,,,,,,,,,,,80%,,,60%,60%,20%,,,20%,,,,,,,,0.00%,0.00%,100%,0%,5.17,3.2,6.07,,,,,0,,,0.78,0.75,1.07,77,,68,86,,,,72.30%,,,,,,,,,,,,167,235,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,20%,,,0,,,,,,100%,,26.5,,0.00%,0.00%,,,
62,10,China,Chongqing,3,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Severe 60-69,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,0.00%,33.30%,,,,,,,,,66.70%,,,,,,,,,,,,,,,33.30%,,,66.70%,66.70%,100%,,,100%,,,,,,,,0.00%,0.00%,100%,0%,6.34,5.43,6.68,,,,,0,,,0.69,0.63,1.43,158,,131,356,,,,82.70%,,,,,,,,,,,,117,121,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0,,,0,,,,,,100%,,15.7,,0.00%,0.00%,,,
62,11,China,Chongqing,4,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,,Arthur,,1/1/2020,3/1/2020,60,Subgroup,Severe 70-79,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,,50.00%,50.00%,10.3,,,,,,,,25%,,,,,,,,,,,,,,,50%,,,75%,100%,50%,,,50%,,,,,,,,0.00%,0.00%,100%,0%,3.05,2.25,3.85,,,,,0,,,0.5,0.4,0.97,130.5,,121,140,,,,69.80%,,,,,,,,,,,,121,111,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,25%,,,0,,,,,,100%,,21.25,,0.00%,0.00%,,,
63,0,China,Wuhan,403,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf,English,,Kim,,1/30/2020,2/25/2020,26,Top-level,General,Positive only,End-point only,Both,Both,Yes,Both,All,NA,,56,,39,68,,47.90%,,,,,,,,,,,,7.20%,10.20%,43.40%,28%,14.10%,8.90%,,6.90%,,,1.70%,9.70%,,,,79.20%,,,10.20%,2%,,,0.50%,3.50%,,1.00%,0.50%,,2%,,,,,,,5.5,4.11,7.3,126.9,,109.2,144.6,1,,,1.06,0.75,1.49,192,,148,251,12.8,10,17.5,3.57,,,,25.5,,,,,,,,,,,,,,,,86.60%,97.80%,,,,,,,49.10%,,26.30%,13.90%,5.70%,,41.20%,,,,,35.50%,,,,,,21.60%,,20.60%,14.10%,19.20%,,,100%,,75.19%,,,,24.81%,24.81%,,,
63,1,China,Wuhan,100,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf ,English,,Kim,,1/30/2020,2/25/2020,26,Subgroup,Died,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,Both,All,NA,,71,,65,80,,57%,,,,,,,,,,,,9%,10%,77%,60%,25%,16%,,17%,,,3%,22%,,,,87%,,,4%,2%,,,0%,2%,,1.00%,0%,,0%,,,,,,,8.58,5.13,12.34,125,,105.4,144.6,1,,,0.73,0.46,0.92,169,,121,219,17.4,12.7,24.7,7.09,,,,95,,,,,,,,,,,,,,,,99%,96%,,,,,,,66%,,74%,48%,16%,,74%,,,,,90%,,,,,,71%,,65%,43%,58%,,,100%,,0%,,,,100.00%,100.00%,,,
63,2,China,Wuhan,303,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf,English,,Kim,,1/30/2020,2/25/2020,26,Subgroup,Discharged,Positive only,End-point only,Both,Discharged only,Yes,Both,All,NA,,49,,37,62,,44.90%,,,,,,,,,,,,6.60%,10.20%,32.30%,17.50%,10.60%,6.60%,,3.60%,,,1.30%,5.60%,,,,76.60%,,,12.20%,2%,,,0.70%,4%,,1.00%,0.70%,,2.60%,,,,,,,5.03,3.98,6.5,127.5,,110.4,144.6,1,,,1.18,0.9,1.62,205,,153,264,11.9,9.5,15.4,3.1,,,,23.8,,,,,,,,,,,,,,,,82.90%,98.30%,,,,,,,43.60%,,10.60%,2.60%,2.30%,,30.40%,,,,,17.50%,,,,,,5.30%,,5.90%,4.60%,6.30%,,,100%,,100%,,,,0.00%,0.00%,,,
64,0,China,Qingdao/Wuhan,74,Epidemiological and Clinical Characteristics of Children with Coronavirus Disease 2019,MedRxiv,Wu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20027078v1.full.pdf,English,Pediatric cases only,Kim,,1/20/2020,2/27/2020,38,Top-level,,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,NA,,6,,0.1,15.08,,59.46%,,,95.59%,,,,,,,,,0%,0%,0%,,,,,,,,,,,,,27.03%,38.6,40.1,32.43%,2.70%,2.70%,2.70%,0%,6.76%,,4.05%,,4.05%,,,,40.54%,,,,7.68,,,,,,,1,,,3.73,,,,,,,,,,,,,,1.9,,,,,,,,,,,,,,,,35.52%,,0%,0%,,,,1.30%,,,0%,1.30%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,100%,,100%,,11,,0.00%,0.00%,,,
65,0,Japan (Diamond Princess),International,104,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,Comorbidity breakdown only for aggregate. Labs are discretized but could be usable if we end up binning,Holly,,2/11/2020,2/26/2020,15,Top-level,General,Positive only,,Survivors only,Both,,,All,,68,,,46.75,75,,,,,,,,,,,,,,,,50%,,6.70%,,,,,3.80%,,,,,,28.80%,,,27.90%,6.70%,9.60%,,,,,7.70%,,,15.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,,
65,1,Japan (Diamond Princess),International,76,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,Comorbidity breakdown only for aggregate. Labs are discretized but could be usable if we end up binning,Holly,,2/11/2020,2/26/2020,15,Subgroup,"Non-severe (asymptomatic, mild)",Positive only,,Survivors only,Both,,,Mild only,,66.5,,,44.75,74,,,,,,,,,,,,,,14.50%,,44.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,,,,
65,2,Japan (Diamond Princess),International,28,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,Comorbidity breakdown only for aggregate. Labs are discretized but could be usable if we end up binning,Holly,,2/11/2020,2/26/2020,15,Subgroup,Severe,Positive only,,Survivors only,Both,,,Severe/Critical Only,,72.5,,,55.25,76.5,,,,,,,,,,,,,,25%,,64.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.10%,,,,,,,,,,1.22%,,,,1.22%,2.44%,,,,,,,,,,na,,,,,,,,
66,0,South Korea,Nationwide,7755,"Coronavirus disease-19: The First 7,755 Cases in the Republic of Korea",MedRxiv,KCDC,https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1,English,"More data on fatalities, so might make more sense to only report on this subset; might also be more data on the KCDC website",Matthew,,2/11/2020,2/26/2020,15,Top-level,,Positive only,,Both,Both,No,,All,NA,,,,,,,38%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,1.00%,,,,
66,1,South Korea,Nationwide,66,"Coronavirus disease-19: The First 7,755 Cases in the Republic of Korea",MedRxiv,KCDC,https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1,English,"More data on fatalities, so might make more sense to only report on this subset; might also be more data on the KCDC website",Matthew,,2/11/2020,2/26/2020,15,Subgroup,Died,Positive only,,Non-Survivors only,Non-discharged only,No,,All,NA,77,,,45,84,,56%,,,,,,,,,4.5,0,11,,,97%,,,15.90%,,,11.10%,,7.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,100.00%,,,,
67,0,China,Wuhan,82,"The clinical and epidemiological features and hints of 82 confirmed COVID-19 pediatric cases aged 0-16 in Wuhan, China",MedRxiv,Yu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.15.20036319v1.full.pdf,English,,Galit,,2/1/2020,2/20/2020,19,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,4,3.39,,0,6,0,62.20%,,100%,,,,,,,,,,0%,0%,9%,,,,,,,,,9%,,,,62.19%,,,62.19%,2.44%,,,,,,,,,,,,9.76%,,,,8.76,,,,,,,0,,,,,,248,,,,,,,,34.57,44.43,64.97,18.22,30.66,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,9.80%,73.17%,,11.2,,0.00%,0.00%,,,
68,0,China,Wuhan,158,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/2020,2/25/2020,55,Top-level,All,Positive only,End-point only,Both,Both,Yes,Both,All,Both,66,,,56,73.3,,55.70%,13.90%,0.60%,13.30%,,,,,,8,4,13,5.70%,3.20%,,43%,50%,18.40%,,8.20%,4.40%,,10.10%,5.10%,,,,81%,,,60.80%,41.10%,3.20%,,13.90%,58.20%,,11.40%,3.80%,53.20%,,,,,,,,5.9,4.2,8.1,,,,,1,,,0.94,0.62,1.23,197,,138,267,11.4,8.3,15.9,3.9,26,28.5,,37.9,,,,,,,,356,171,,,,,,,85.40%,98.70%,,,,,,,22.80%,,64.60%,15.80%,7.60%,0,39.90%,,,,,,,29.70%,,,27.80%,,,34.80%,12%,32.30%,,,100.00%,22.80%,na,,13,,27.80%,,,,
68,1,China,Wuhan,79,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/2020,2/25/2020,55,Subgroup,non-diabetic,Positive only,End-point only,Both,Both,Yes,Both,All,Both,66,,,56,74,,55.70%,20.30%,0%,20.30%,,,,,,8,5,12,6.30%,3.80%,,25.30%,0%,10.10%,,8.90%,3.80%,,10.10%,2.50%,,,,79.70%,,,57%,40.50%,5.10%,,7.60%,50.60%,,13.90%,1.30%,50.60%,,,,,,,,6,4,8,,,,,1,,,1,0.63,1.29,209,,158,273,11.7,8.4,15.9,3.8,27.5,30,,35,,,,,,,,374,222,,,,,,,83.50%,98.70%,,,,,,,21.50%,,62%,8.90%,5.10%,0,39.20%,,,,,,,20.30%,,,20.30%,,,22.80%,6.30%,21.50%,,,100%,15.20%,na,,13,,20.30%,,,,
68,2,China,Wuhan,79,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/2020,2/25/2020,55,Subgroup,diabetic ,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,66,,,56,73,,55.70%,7.60%,1.30%,6.30%,,,,,,8,4,14,5.10%,2.50%,,60.80%,100%,26.60%,,7.60%,5.10%,,10.10%,7.60%,,,,82.30%,,,64.60%,41.80%,1.30%,,20.30%,65.80%,,8.90%,6.30%,55.70%,,,,,,,,5.8,4.5,8.2,8.2,,6.6,9,1,,,0.81,0.56,1.22,185,,133.5,259.3,11,7.9,16,4.3,25.5,27.5,,39.9,,,,,,,,280,142,,,,,,,87.30%,98.70%,,,,,,,24.10%,,67.10%,22.80%,10.10%,0,40.50%,,,,,,,39.20%,,,35.40%,,,46.80%,17.70%,43%,,,100%,30.40%,na,,13,,35.40%,,,,
68,3,China,Wuhan,51,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/2020,2/25/2020,55,Subgroup,diabetic - survivors,Positive only,End-point only,Survivors only,Discharged only,Yes,Both,All,Both,63,,,55,70,,49%,5.90%,2.00%,3.90%,,,,,,8.5,4,15,2%,2%,,49%,100%,17.60%,,3.90%,3.90%,,11.80%,2%,,,,84.30%,,,66.70%,33.30%,2%,,23.50%,62.70%,,11.80%,5.90%,54.90%,,,,,,,,5.3,4,7.1,7.6,,6.6,8.6,1,,,0.97,0.71,1.38,197,,146,289,9.5,7.8,13.4,3.4,27,24,,15.3,,,,,,,,382,157,,,,,,,80.40%,87.30%,,,,,,,19.60%,,58.80%,7.80%,2%,0,33.30%,,,,,,,5.90%,,,2%,,,19.60%,0%,25.50%,,,100%,11.80%,na,,16,,0.00%,,,,
68,4,China,Wuhan,28,"Diabetic patients with COVID-19, characteristics and outcome — A two-centre, retrospective, case control study",Lancet Diabetes and Endocrinology,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551369,English,Can split by diabetic vs. non-diabetic,Agni,,1/1/2020,2/25/2020,55,Subgroup,diabetic - non survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,Both,Severe/Critical Only,Both,74.5,,,64.3,81.8,,67.90%,10.70%,0%,10.70%,,,,,,8,3,13,10.70%,3.60%,,82.10%,100%,42.90%,,14.30%,7.10%,,7.10%,17.90%,,,,78.60%,,,60.70%,57.10%,0%,,14.30%,71.40%,,3.60%,7.10%,57.10%,,,,,,,,8,5.5,13.6,9.9,,7.8,11,1,,,0.7,0.38,0.82,174,,114,202,14.2,8,24.3,6.9,23,41,,86.1,,,,,,,,202.5,78,,,,,,,100%,100%,,,,,,,32.10%,,82.10%,50%,25%,0,53.60%,,,,,,,100%,,,96.40%,,,96.40%,50%,75%,,,100%,64.30%,na,,5,,100.00%,,,,
69,0,China,Shenzhen,6,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/2020,1/24/2020,14,Top-level,All,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,All,Non-ventilation only,50,46.17,17.98436475,36,65,0%,50%,33%,0%,33%,4.5,4.5,3,6,7.8,7,7,9,,,66.67%,33.33%,16.67%,0%,,0%,16.67%,0%,0%,16.67%,,,,83.33%,37.7,,83.33%,,,,50%,50%,16.67%,33.33%,,,16.67%,,,,16.67%,16.67%,0%,5.2,4.3,6.5,148,,131,152,1,,,1.7,0.7,2.7,196.5,,166.75,201,,,,4.05,19.23,24.18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,,83.33%,0%,0%,0%,,,0.00%,,,,
69,1,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/2020,1/24/2020,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,65,65,,65,65,0%,0%,100%,0%,100%,,,,,7,7,7,7,,,100%,100%,0%,0%,,0%,100%,0%,0%,0%,,,,100%,39,,100.00%,,,,100%,100%,0%,0%,,,0%,,,,0%,0%,0%,4.8,4.8,4.8,131,,131,131,1,,,0.6,0.6,0.6,157,,157,157,,,,4,14.2,20.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,,
69,2,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/2020,1/24/2020,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Severe/Critical Only,Non-ventilation only,66,66,,66,66,0%,100%,0%,0%,0%,,,,,6,6,6,6,,,100%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,100%,39,,100.00%,,,,100%,100%,0%,0%,,,0%,,,,100%,100%,0%,4.2,4.2,4.2,156,,156,156,1,,,0.7,0.7,0.7,118,,118,118,,,,3.2,13.9,23.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,,
69,3,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/2020,1/24/2020,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,37,37,,37,37,0%,0%,100%,0%,100%,,,,,9,9,9,9,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,100%,36.2,,100.00%,,,,0%,0%,100%,100%,,,100%,,,,0%,0%,0%,5.6,5.6,5.6,150,,150,150,1,,,2.2,2.2,2.2,224,,224,224,,,,3.1,25.9,27.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,,
69,4,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/2020,1/24/2020,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,36,36,,36,36,0%,100%,0%,0%,0%,,,,,10,10,10,10,,,100%,0%,0%,0%,,0%,0%,0%,0%,100%,,,,100%,36.5,,100%,,,,0%,0%,0%,100%,,,0%,,,,0%,0%,0%,11.4,11.4,11.4,152,,152,152,1,,,2.7,2.7,2.7,196,,196,196,,,,8.1,20.2,18.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,,
69,5,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Asymptomatic; not admitted to hospital,Ryan,,1/10/2020,1/24/2020,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,10,10,,10,10,0%,100%,0%,0%,0%,,,,,,,,,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,0%,36.5,,0%,,,,0%,0%,0%,0%,,,0%,,,,0%,0%,0%,6.5,6.5,6.5,146,,146,146,1,,,2.8,2.8,2.8,197,,197,197,,,,3.2,23.9,28.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,,0%,0%,0%,0%,,,0.00%,,,,
69,6,China,Shenzhen,1,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,,Ryan,,1/10/2020,1/24/2020,14,Subgroup,Single patient,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,63,63,,63,63,0%,0%,0%,0%,0%,,,,,7,7,7,7,,,100%,0%,100%,0%,,,0%,0%,0%,0%,,,,100%,39,,100%,,,,100%,100%,0%,0%,,,0%,,,,0%,0%,0%,4.3,4.3,4.3,130,,130,130,1,,,1.2,1.2,1.2,205,,205,205,,,,2.7,17.3,27.6,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,,0.00%,,,,
70,0,China,Wuhan,101,"Clinical characteristics of 101 non-survivors hospitalized with COVID-19—A single center, retrospective study",Lancet,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550014,English,,Galit,,1/1/2020,2/15/2020,45,Top-level,All,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,,Severe/Critical Only,Both,71,,,60,80,,59.41%,100%,100%,,,,,,,,,,,,82%,58.42%,21.78%,24%,,13.86%,7%,,11%,0%,,,,81.19%,,,55.45%,58.42%,4.95%,,6%,35.64%,,10%,3%,,,,,0%,0%,0%,100%,9.7,9.042,10.358,,,,,1,,,0.76,0.681,0.839,178.2,,167.37,189.03,25.01,18.324,31.696,8.466,55.99,116.8,,107.9,,,,,,,,197.9,130.4,,,,,,,98%,96%,,,,,,,,,,40.59%,13.86%,,43.56%,4.95%,,,,,,,,,,,,,,,,,100%,,0%,,4,,100.00%,100.00%,,,
70,1,China,Wuhan,48,"Clinical characteristics of 101 non-survivors hospitalized with COVID-19—A single center, retrospective study",Lancet,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550014,English,,Ryan,,1/1/2020,2/15/2020,45,Subgroup,<=3d course of disease group,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,,Severe/Critical Only,Both,72,,,59,78,,58%,100%,100%,,,,,,,,,,,,77%,54%,19%,18.75%,,8%,6%,,4%,0%,,,,79%,,,48%,58%,2%,,2%,40%,,8%,2%,,,,,0%,0%,0%,100%,12.36,11.11,13.61,,,,,1,,,0.7,0.62,0.78,185.2,,163.95,206.45,28.94,16.95,40.93,11.23,88.64,219.2,,123.4,,,,,,,,203.3,120.7,,,,,,,98%,97.92%,,,,,,,,,,22.92%,16.67%,,35.42%,4.17%,,,,,,,,,,,,,,,,,100%,,0%,,2,,100.00%,100.00%,,,
70,2,China,Wuhan,53,"Clinical characteristics of 101 non-survivors hospitalized with COVID-19—A single center, retrospective study",Lancet,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550014,English,,Ryan,,1/1/2020,2/15/2020,45,Subgroup,<=3d course of disease group,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,,Severe/Critical Only,Both,71,,,59,81,,60%,100%,100%,,,,,,,,,,,,85%,62%,25%,28.30%,,19%,8%,,17%,0%,,,,83%,,,62%,58%,9%,,9%,32%,,11%,8%,,,,,0%,0%,0%,100%,7.72,7.21,8.23,,,,,1,,,0.69,0.64,0.74,173,,162.5,183.5,22.38,14.61,30.15,6.48,34.15,46.15,,94.1,,,,,,,,195.6,151,,,,,,,98%,94.34%,,,,,,,,,,56.60%,11.32%,,50.94%,5.66%,,,,,,,,,,,,,,,,,100%,,0%,,7,,100.00%,100.00%,,,
71,1,China,Wuhan,55,"Clinical Characteristics of 55 Cases of Deaths with COVID-19 Pneumonia in Wuhan, China: Retrospective Case Series",Lancet,Yao et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550019,English,,Galit,,1/26/2020,2/18/2020,23,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,,Yes,,Severe/Critical Only,Both,65,70.7,,60,80,0%,67%,100%,100%,,,,,,,,,,,,73%,60%,26%,,,22%,7%,,9%,0%,,,,96%,,,62%,96%,4%,,93%,93%,,4%,4%,,,,,0%,0%,0%,100%,7.85,4.84,12.79,125,,105,145,1,,,0.55,0.41,0.8,160.5,,93.3,227.7,14.1,8.6,19.9,7.58,25,43,44,84.9,,,,,,,,,,,,,,,,96%,,,,,,,,,,,21.80%,,,,7.30%,,,,,,,,,,,,,,,,,100%,,0%,,,,100.00%,100.00%,,,
72,0,China,Wuhan,140,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Treatments and outcomes not reported as patients had largely not been discharged,Ryan,,1/16/2020,2/3/2020,18,Top-level,All,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,57,,,30,75,2.10%,50.70%,10.70%,0%,0%,,,,,8,8,7,10,1.40%,,64.30%,30%,12.10%,5.00%,,1.40%,,,,10%,,,,91.70%,,,75%,36.70%,,,,75%,36.70%,12.90%,17.30%,12.20%,,,,,41.40%,,,4.7,3.7,6.7,,,,,1,,34.2,0.8,0.7,1,,,,,,,,,,,,34.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,,
72,1,China,Wuhan,82,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Treatments and outcomes not reported as patients had largely not been discharged,Ryan,,1/16/2020,2/3/2020,18,Subgroup,Nonsevere,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,51.5,,,31,71,3.70%,46.30%,13.40%,0%,0%,,,,,8,8,6,10,0%,,53.70%,24.40%,11.00%,3.70%,,0%,,,,10%,,,,88.10%,,,76.10%,29.90%,,,,76.10%,29.90%,11.00%,23.20%,11.00%,,,,,0%,,,4.5,3.5,5.9,,,,,1,,28.7,0.8,0.7,1.1,,,,,,,,,,,,28.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,,
72,2,China,Wuhan,58,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Treatments and outcomes not reported as patients had largely not been discharged,Ryan,,1/16/2020,2/3/2020,18,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,64,,,33,77,0%,56.90%,6.90%,0%,0%,,,,,7,7,6,10,3.40%,,79.30%,37.90%,13.80%,6.90%,,3.40%,,,,10%,,,,96.20%,,,73.60%,45.30%,,,,73.60%,45.30%,15.80%,8.80%,14.00%,,,,,100%,,,5.3,4,9,,,,,1,,47.6,0.7,0.6,0.9,,,,,,,,,,,,47.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,na,,,,,,,,
73,0,China,Wuhan,36,"Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China",MedRxiv,Huang et. al.,https://www.medrxiv.org/content/medrxiv/early/2020/03/05/2020.02.27.20029009.full.pdf,English,,Sam,,1/21/2020,2/14/2020,24,Top-level,All,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,ΝΑ,Severe/Critical Only,NA,69.22,69.22,18.890544,62.8844,75.5556,,69.44%,,,,,,,,,,,,11.11%,,,58.33%,19.44%,13.89%,,11.11%,2.78%,,8.33%,,,,,94.44%,,,77.78%,58.33%,,22.22%,2.78%,47.22%,,8.33%,,,,,,,0%,100%,0%,7.67,4.1,10.97,123.74,,111.14294,136.33706,0,,,0.67,0.44758,0.89242,167.21,,115.39962,219.02038,11.21,7.5,19.2,6.64,26,43,,106.2,100.6,,,,,,,,,,,,,,,100%,97.22%,,,,,,,55.56%,,97.22%,52.78%,25%,,69.44%,,,,,100%,,100%,,,,,,,2.78%,,,,100%,,0%,,,,100.00%,100.00%,,,
74,0,Chile,Chile,922,SITUACIÓN EPIDEMIOLÓGICA COVID-19. CHILE al 23 de marzo de 2020,Departamento de Epidemiología. Ministerio de Salud de Chile,Departamento de Epidemiología. Ministerio de Salud de Chile,https://www.dropbox.com/s/cj3p12oncrewh72/Informe_10_COVID_19_Chile.pdf.pdf.pdf?dl=0,Spanish,,Galit,Galit,3/1/2020,3/23/2020,22,Top-level,All,Positive only,End-point and active,Both,,,,,,34,,,29,47,,49%,,,,,,,,,,,,,,,,,,,,,,,,,,,9%,,,52%,57%,52%,,4%,,,,47%,,45%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.20%,,na,,,,0.20%,,,,
75,0,USA,Nationwide,12,First 12 patients with coronavirus disease 2019 (COVID-19) in the United States,MedRxiv,The COVID-19 Investigation Team,10.1101/2020.03.09.20032896,English,,Ryan,,1/20/2020,2/22/2020,33,Top-level,All,Positive only,End-point and active,Both,Both,No,Both,All,Both,53,,,,,,67%,100%,75%,17%,,,,,1,1,0,3,8.33%,,16.67%,16.67%,8.33%,16.67%,,8.33%,0.00%,0%,0%,33.33%,,,,58.33%,,,66.67%,8.33%,25%,,,41.67%,,8.33%,,,8.33%,8.33%,,0%,58.33%,50%,8.33%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,,0%,0%,,,,,,,,58.33%,8.33%,92%,4,12.71428571,29,0%,0%,,,
75,1,USA,Nationwide,7,First 12 patients with coronavirus disease 2019 (COVID-19) in the United States,MedRxiv,The COVID-19 Investigation Team,10.1101/2020.03.09.20032896,English,,Ryan,,1/20/2020,2/22/2020,33,Subgroup,Hospitalized patients,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,55,,,,,,71.40%,100%,,,,,,,2,1,1,3,14.28%,,57.14%,14.28%,14.28%,14.28%,,14.28%,0%,0%,0%,28.57%,,,,85.27%,,38.544,85.71%,14.28%,14.28%,,,28.57%,,14.28%,,,,,,0%,100%,85.72%,14.28%,3.65,3.3,3.9,,,,,1,,,,,,,,,,,,,,180,120.14,,,,,,,,,,,,,,,,,,71.42%,42.85%,0%,0%,,,,0%,0%,,14.28%,,,,,,,,0%,,,,,0%,0%,,,,,,,,100%,14.28%,86%,4,12.71,32,0%,0%,,,
76,0,China,,36,Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming,MedRxiv,,10.1101/2020.02.28.20029173,English,"binned labs, no deaths",EXCLUDE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
77,0,China,Wuhan,109,Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome,MedRxiv,Liu et al. ,10.1101/2020.02.17.20024166,English,,Holly,,1/2/2020,2/12/2020,41,Top-level,All,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,Both,55,,,43,66,,54.10%,,,,,,,,5,5,3,7,,,,33.90%,11%,,,3.70%,,,9.20%,,,,,82.60%,,,61.50%,,,,,56.90%,,11%,,,,,,0%,,,,5.2,4,7,,,,,,,65,0.9,0.5,1.2,,,,,9,6.5,13.4,3.6,23,30,,3.1,,,,,,,,,,,,,,,,97.20%,98.20%,,,,,,,,,25.70%,,0.00%,,,,,,,,,,,,,,,,,,,,100%,,,,15,,28.40%,,,,
77,1,China,Wuhan,56,Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome,MedRxiv,Liu et al.,10.1101/2020.02.17.20024166,English,Subgroup without ARDS,Ryan,,1/2/2020,2/12/2020,41,Top-level,All,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,Both,49,,,37,59,,55.40%,,,,,,,,4,4,2,6,,,,28.60%,1.80%,,,3.60%,,,3.60%,,,,,85.70%,,,64.30%,,,,,46.40%,,10.70%,,,,,,0%,,,,4.9,3.8,6.2,,,,,,,64,1,0.8,1.4,,,,,8.3,6.8,11.7,3.2,23,29,,2,,,,,,,,,,,,,,,,94.60%,98.20%,,,,,,,,,3.60%,,0.00%,,,,,,,,,,,,,,,,,,,,100%,,,,,,8.90%,,,,
77,2,China,Wuhan,53,Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome,MedRxiv,Liu et al.,10.1101/2020.02.17.20024166,English,Subgroup with ARDS,Ryan,,1/2/2020,2/12/2020,41,Top-level,All,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,Both,61,,,52,70,,52.80%,,,,,,,,7,7,5,9,,,,39.60%,20.80%,,,3.80%,,,15.10%,,,,,79.20%,,,58.50%,,,,,67.90%,,11.30%,,,,,,0%,,,,5.4,4.5,8,,,,,,,67,0.7,0.4,1.1,,,,,10.5,6.2,14.8,4.1,24,31,,4.9,,,,,,,,,,,,,,,,100%,98.10%,,,,,,,,,49.10%,,0.00%,,,,,,,,,,,,,,,,,,,,100%,,,,,,49.06%,,,,
78,0,China,Nanjing,24,"Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China",MedRxiv,,10.1101/2020.02.20.20025619,English, asymptomatic; also break down by CT but not including this for now,Holly,,1/28/2020,2/18/2020,21,Top-level,All,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,32.5,,,19,57,,33.30%,,33.30%,,,8,6,9,,,,,4.20%,,,8.30%,8.30%,4.20%,,0%,0%,,4.20%,,,,,20.80%,,,8.30%,,,,,8.30%,4.20%,,,,,,,,,,,,,,132,,120,144,1,,,,,,,,,,,,,,,,,,,,,,,,,,,16.70%,17.40%,0%,8.30%,0%,8.30%,4.20%,87.50%,,,,,,0%,,,,0%,0%,,,,,,0%,,,,,,,,,,,,,,100%,0%,38%,,,9.5,0%,0%,,,
78,1,China,Nanjing,5,"Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China",MedRxiv,,10.1101/2020.02.20.20025619,English, asymptomatic; also break down by CT but not including this for now,Holly,,1/28/2020,2/18/2020,21,Subgroup,Symptomatic,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,53,,,23,65,,0%,,60%,,,8,6,9,,,,,0%,,,0%,0%,0%,,0%,0%,,20%,,,,,100%,,,40%,,,,,40%,20%,,,,,,,,,,,,,,124,,123,129,1,,,,,,,,,,,,,,,,,,,,,,,,,,,40%,40%,0%,0%,0%,0%,0%,100%,,,,,,0%,,,,0%,0%,,,,,,0%,,,,,,,,,,,,,,100%,0%,0%,,,12,0.00%,,,,
78,2,China,Nanjing,19,"Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China",MedRxiv,,10.1101/2020.02.20.20025619,English, asymptomatic; also break down by CT but not including this for now,Holly,,1/28/2020,2/18/2020,21,Subgroup,Asymptomatic,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,32,,,15,57,,42.10%,,26.30%,,,,,,,,,,5.30%,,,10.50%,10.50%,5.30%,,0%,0%,,0%,,,,,0%,,,0%,,,,,0%,0%,,,,,,,,,,,,,,134.5,,120,152,1,,,,,,,,,,,,,,,,,,,,,,,,,,,10.50%,11.10%,0%,10.50%,0%,10.50%,5.30%,84.20%,,,,,,0%,,,,0%,0%,,,,,,0%,,,,,,,,,,,,,,100%,0%,50.00%,,,6,0%,0%,,,
79,0,China,Wuhan,25,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025239,English,"all deaths, patient-level data",Ryan,,1/14/2020,2/13/2020,30,Top-level,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,73,71.88,24.34640352,62,78,,40.00%,,,,,,,,,,,,,,100%,64%,36%,36%,,8%,16%,0%,0%,36%,,,,,,,,,,,,,,,,,,,,,,,,10.84,6.33,13.93,121,,101,134,1,,135.7083333,0.52,0.27,0.69,150,,125,201,,,,9.7652,48.4,84.04,,101.975,,,,,,,,,,80%,36%,36%,28%,,36%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,10.56,,100%,100%,,,
79,1,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025240,English,Patient 1,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,55,55,0,55,55,,0.00%,,,,,,,,,,,,,,100%,0.00%,100.00%,0.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,10.84,10.84,10.84,112,,112,112,0,,43,0.31,0.31,0.31,194,,194,194,,,,10.41,16,30,,86,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,17,,100%,100%,,,
79,2,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025241,English,Patient 2,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,62,62,0,62,62,,100.00%,,,,,,,,,,,,,,100%,100.00%,100.00%,0.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,17.91,17.91,17.91,137,,137,137,0,,428,0.23,0.23,0.23,39,,39,39,,,,17.01,49,67,,96.2,,,,,,,,,,100.00%,0.00%,100.00%,100.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,11,,100%,100%,,,
79,3,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025242,English,Patient 3,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,81,81,0,81,81,,0.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,100.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,14.04,14.04,14.04,122,,122,122,1,,47,0.13,0.13,0.13,125,,125,125,,,,13.72,22,34,,174,,,,,,,,,,100.00%,100.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,17,,100%,100%,,,
79,4,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025243,English,Patient 4,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,72,72,0,72,72,,0.00%,,,,,,,,,,,,,,100%,100.00%,100.00%,100.00%,,100%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,10.08,10.08,10.08,68,,68,68,0,,497,0.52,0.52,0.52,167,,167,167,,,,9,7,18,,178,,,,,,,,,,100.00%,100.00%,0.00%,0.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,10,,100%,100%,,,
79,5,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025244,English,Patient 5,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,83,83,0,83,83,,0.00%,,,,,,,,,,,,,,100%,100.00%,100.00%,100.00%,,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,2.98,2.98,2.98,91,,91,91,0,,209,0.26,0.26,0.26,64,,64,64,,,,2.63,27,56,,82.8,,,,,,,,,,100.00%,0.00%,100.00%,0.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,7,,100%,100%,,,
79,6,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025245,English,Patient 6,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,70,70,0,70,70,,100.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,16.74,16.74,16.74,128,,128,128,0,,113,0.28,0.28,0.28,226,,226,226,,,,15.07,70,107,,203,,,,,,,,,,100.00%,100.00%,100.00%,100.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,8,,100%,100%,,,
79,7,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025246,English,Patient 7,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,73,73,0,73,73,,100.00%,,,,,,,,,,,,,,100%,0.00%,0.00%,100.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,10.27,10.27,10.27,140,,140,140,0,,,0.69,0.69,0.69,233,,233,233,,,,8.9,31,53,,124.3,,,,,,,,,,100.00%,100.00%,100.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,9,,100%,100%,,,
79,8,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025247,English,Patient 8,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,74,74,0,74,74,,0.00%,,,,,,,,,,,,,,100%,0.00%,0.00%,100.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,8.68,8.68,8.68,120,,120,120,0,,58,0.72,0.72,0.72,224,,224,224,,,,7.48,14,34,,141,,,,,,,,,,100.00%,100.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,8,,100%,100%,,,
79,9,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025248,English,Patient 9,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,82,82,0,82,82,,100.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,100.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,11.76,11.76,11.76,174,,174,174,0,,63,0.41,0.41,0.41,262,,262,262,,,,10.98,33,38,,,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,7,,100%,100%,,,
79,10,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025249,English,Patient 10,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,78,78,0,78,78,,100.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,13.93,13.93,13.93,134,,134,134,0,,110,1.12,1.12,1.12,175,,175,175,,,,12.41,51,81,,180,,,,,,,,,,0.00%,100.00%,100.00%,100.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,10,,100%,100%,,,
79,11,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025250,English,Patient 11,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,78,78,0,78,78,,0.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,9.58,9.58,9.58,77,,77,77,0,,242,0.81,0.81,0.81,338,,338,338,,,,8.13,21,38,,,,,,,,,,,,0.00%,0.00%,0.00%,0.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,9,,100%,100%,,,
79,12,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025251,English,Patient 12,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,67,67,0,67,67,,0.00%,,,,,,,,,,,,,,100%,0.00%,100.00%,0.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,12.61,12.61,12.61,139,,139,139,1,,51,1.09,1.09,1.09,139,,139,139,,,,10.76,27,36,,51.4,,,,,,,,,,0.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,7,,100%,100%,,,
79,13,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025252,English,Patient 13,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,94,94,0,94,94,,100.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,100.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,5.63,5.63,5.63,106,,106,106,1,,73,0.53,0.53,0.53,150,,150,150,,,,4.92,44,62,,120,,,,,,,,,,100.00%,100.00%,100.00%,100.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,14,,100%,100%,,,
79,14,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025253,English,Patient 14,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,69,69,0,69,69,,0.00%,,,,,,,,,,,,,,100%,0.00%,0.00%,0.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,11.01,11.01,11.01,115,,115,115,0,,51,0.55,0.55,0.55,24,,24,24,,,,10.31,24,27,,110,,,,,,,,,,100.00%,100.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,13,,100%,100%,,,
79,15,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025254,English,Patient 15,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,90,90,0,90,90,,100.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,5.65,5.65,5.65,130,,130,130,0,,60,0.59,0.59,0.59,128,,128,128,,,,4.56,17,43,,33.8,,,,,,,,,,100.00%,0.00%,100.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,9,,100%,100%,,,
79,16,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025255,English,Patient 16,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,75,75,0,75,75,,0.00%,,,,,,,,,,,,,,100%,100.00%,100.00%,0.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,13.35,13.35,13.35,150,,150,150,0,,49,0.52,0.52,0.52,239,,239,239,,,,12.62,21,37,,39,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,7,,100%,100%,,,
79,17,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025256,English,Patient 17,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,56,56,0,56,56,,0.00%,,,,,,,,,,,,,,100%,0.00%,0.00%,0.00%,,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,18.77,18.77,18.77,45,,45,45,0,,69,1.1,1.1,1.1,133,,133,133,,,,17.31,16,39,,74,,,,,,,,,,0.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,7,,100%,100%,,,
79,18,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025257,English,Patient 18,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,59,59,0,59,59,,0.00%,,,,,,,,,,,,,,100%,100.00%,100.00%,0.00%,,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,6.33,6.33,6.33,123,,123,123,0,,43,0.48,0.48,0.48,139,,139,139,,,,5.39,68,32,,7.6,,,,,,,,,,100.00%,0.00%,0.00%,100.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,11,,100%,100%,,,
79,19,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025258,English,Patient 19,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,56,56,0,56,56,,100.00%,,,,,,,,,,,,,,100%,100.00%,100.00%,0.00%,,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,9.53,9.53,9.53,84,,84,84,0,,175,0.16,0.16,0.16,146,,146,146,,,,9.25,515,1082,,,,,,,,,,,,100.00%,0.00%,100.00%,100.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,17,,100%,100%,,,
79,20,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025259,English,Patient 20,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,74,74,0,74,74,,100.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,20.17,20.17,20.17,139,,139,139,0,,71,1.43,1.43,1.43,201,,201,201,,,,17.92,48,59,,,,,,,,,,,,0.00%,0.00%,100.00%,100.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,8,,100%,100%,,,
79,21,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025260,English,Patient 21,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,55,55,0,55,55,,0.00%,,,,,,,,,,,,,,100%,0.00%,0.00%,0.00%,,0%,100%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,3.98,3.98,3.98,121,,121,121,0,,51,0.68,0.68,0.68,121,,121,121,,,,2.99,26,32,,148.1,,,,,,,,,,100.00%,100.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,10,,100%,100%,,,
79,22,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025261,English,Patient 22,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,64,64,0,64,64,,0.00%,,,,,,,,,,,,,,100%,0.00%,0.00%,0.00%,,0%,100%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,12.7,12.7,12.7,128,,128,128,0,,26,0.14,0.14,0.14,120,,120,120,,,,12.19,20,20,,68,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,20,,100%,100%,,,
79,23,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025262,English,Patient 23,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,74,74,0,74,74,,0.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,,0%,100%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,2.62,2.62,2.62,87,,87,87,0,,29,0.17,0.17,0.17,92,,92,92,,,,2,13,24,,80.7,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,19,,100%,100%,,,
79,24,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025263,English,Patient 24,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,56,56,0,56,56,,0.00%,,,,,,,,,,,,,,100%,100.00%,0.00%,100.00%,,0%,100%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,17.69,17.69,17.69,101,,101,101,0,,580,0.53,0.53,0.53,200,,200,200,,,,16.36,17,23,,,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,5,,100%,100%,,,
79,25,China,Wuhan,1,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025264,English,Patient 25,Ryan,,1/14/2020,2/13/2020,30,Subgroup,Nonsurvivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,100,100,0,100,100,,100.00%,,,,,,,,,,,,,,100%,0.00%,100.00%,100.00%,,100%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,2.25,2.25,2.25,115,,115,115,0,,119,0.27,0.27,0.27,152,,152,152,,,,1.81,13,29,,41.6,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,100%,,4,,100%,100%,,,
80,0,China,Chongqing,51,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China",MedRxiv,Liu et al.,10.1101/2020.02.20.20025536,English,incl detailed lab data,Holly,,1/20/2020,2/11/2020,22,Top-level,All,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,All,Both,45,,,34,51,,62.70%,92.30%,84.30%,,,,,,,,,,,,,7.80%,7.80%,,,,,,,,,,,84.30%,,,74.50%,21.60%,9.80%,31.40%,11.80%,43.10%,,7.80%,5.90%,,,,,,,,,5.4,4.1,7.6,136,,123,152,1,,,1.1,0.7,1.6,189,,134,235,,,,3.7,18,21,,105,0,0.28,40,67,4.1,52,0.04,,,,,,,,,21.60%,100%,100%,,,,,,7.80%,,15.70%,11.80%,2%,,,,,,,,,,,,,,,,,,,,100%,,100%,,,,2%,2%,,,
80,1,China,Chongqing,44,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China",MedRxiv,Liu et al.,10.1101/2020.02.20.20025536,English,incl detailed lab data,Holly,,1/20/2020,2/11/2020,22,Subgroup,Non-severe,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,Non-ventilation only,44,,,33,49,,63.70%,,,,,,,,,,,,,,,6.80%,0%,,,,,,,,,,,84.10%,,,72.70%,11.40%,11.40%,31.80%,11.40%,36.40%,,9.10%,6.80%,,,,,,,,,5.2,4.1,7.6,136,,123,152,1,,,1.3,0.9,1.7,192,,139,237,,,,3.5,18,21,,75,0,0.28,41,68,4.1,59,0.04,,,,,,,,,9%,100%,100%,,,,,,0%,,4.50%,0%,0%,,,,,,,,,,,,,,,,,,,,100%,,100%,,,,0%,0%,,,
80,2,China,Chongqing,7,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China",MedRxiv,Liu et al.,10.1101/2020.02.20.20025536,English,incl detailed lab data,Holly,,1/20/2020,2/11/2020,22,Subgroup,Severe,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,Severe/Critical Only,Both,52,,,44,60,,57.10%,,,,,,,,,,,,,,,14.30%,57.10%,,,,,,,,,,,85.70%,,,85.70%,85.70%,0%,28.60%,14.30%,85.70%,,0%,0%,,,,,,,,,5.7,3.5,10.7,132,,121,152,1,,,0.37,0.3,0.6,150,,116,225,,,,5.2,26,29,,1357,4.6,0.6,35,67,5.1,42,0.1,,,,,,,,,100%,100%,100%,,,,,,57.10%,,85.70%,85.70%,14.30%,,,,,,,,,,,,,,,,,,,,100%,,100%,,,,14.30%,14.30%,,,
81,0,China,Wuhan,110,"Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China",MedRxiv,,10.1101/2020.03.02.20029306,English,Overall; no outcomes as most patients still hospitalized,Ryan,,1/1/2020,2/10/2020,40,Top-level,Patients with pneumonia,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,All,NA,45,,,,,,43.63%,,,,,,,,,,,,23.63%,20.91%,,20.91%,13.63%,6.36%,,5.46%,,,,,,,,81.82%,,,61.82%,32.73%,,,,37.28%,,,,,,,,0%,65.45%,34.55%,0%,5.21,4.04,6.68,131.55,,114.33,148.76,0,,62.18,1.00,0.55,1.45,167.41,,137.59,206.20,,,,3.68,20.49,25.80,,2.06,,,,,,,,,,0.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,0%,,,,0%,,,,
81,1,China,Wuhan,110,"Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China",MedRxiv,,10.1101/2020.03.02.20029307,English,Severe Pneumonia,Ryan,,1/1/2020,2/10/2020,40,Subgroup,Severe pneumonia,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,70,,,,,,63.16%,,,,,,,,,,,,23.68%,10.53%,,39.47%,21.05%,7.89%,,10.53%,,,,,,,,86.84%,,,55.26%,39.47%,,,,26.32%,,,,,,,,0%,0%,100%,0%,5.2,3.9,6.46,129.87,,110.48,149.26,0,,74.75,0.6,0.29,0.91,144.5,,110.75,167.75,,,,4.26,21.9,36.8,,4.98,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,0%,,,,0.00%,,,,
81,2,China,Wuhan,110,"Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China",MedRxiv,,10.1101/2020.03.02.20029308,English,Non-severe Pneumonia,Ryan,,1/1/2020,2/10/2020,40,Subgroup,Non-severe pneumonia,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,All,NA,35,,,,,,33.33%,,,,,,,,,,,,23.61%,26.39%,,11.11%,9.72%,5.56%,,2.78%,,,,,,,,79.17%,,,65.28%,29.17%,,,,43.06%,,,,,,,,0%,100%,0%,0%,5.21,4.11,6.8,132.43,,116.36,148.5,0,,55.55,1.21,0.68,1.74,179.5,,151.75,226.5,,,,3.38,19.75,20,,0.52,,,,,,,,,,0.00%,0.00%,0.00%,0.00%,,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,0%,,,,0.00%,,,,
82,0,China,Chongqing,46,Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults,MedRxiv,Liao et al.,10.1101/2020.03.10.20032136,English,adolescents/young adults,Holly,,1/25/2020,2/23/2020,29,Top-level,All,Positive only,End-point and active,Survivors only,Both,Yes,ΝΑ,All,NA,26.2,,,,,,52.20%,95.60%,47.80%,47.80%,7.2,,,,,,,,10.90%,28.90%,13%,,,,,,,,,,,,,69.10%,,,81%,2.40%,19.10%,38.10%,7.10%,19.10%,7.10%,4.80%,2.40%,9.50%,,,7.10%,8.70%,,89.10%,2.20%,5,4.1,6.7,139.5,,130,151,1,,,1.3,1,1.8,192.5,,156,237,8.7,5.9,14.6,3.4,17.9,18.3,,26,,0.3,,61.5,3.4,57,0.03,,,,,,,,,,100%,,,,,,,,,84.80%,,,,,,,,0%,0,0%,0%,,0,0,0,0,0,6.50%,0,0,0,100.00%,,78.30%,,,12.6,0%,0%,,,
82,1,China,Chongqing,14,Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults,MedRxiv,Liao et al.,10.1101/2020.03.10.20032136,English,adolescents/young adults,Holly,,1/25/2020,2/23/2020,29,Subgroup,Adolescents (10-24 yrs),Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,17.5,,,,,,50%,100%,64.30%,35.70%,,,,,,,,,7.10%,21.40%,7.10%,,,,,,,,,,,,,58.30%,,,91.70%,0%,16.70%,50%,8.30%,16.70%,16.70%,16.70%,0%,0%,,,8.30%,14.30%,,85.70%,0%,5.4,4.5,6.7,147,,133,151,1,,,1.4,1.1,2.3,183,,156,227,9,5.9,24.8,3.8,16.3,16.6,,32,,0.2,,62.5,3.9,53,0.04,,,,,,,,,,100%,,,,,,,,,64.30%,,,,,,,,0%,0,0%,0%,,0,0,0,0,0,7.10%,0,0,0,100.00%,0%,85.70%,,,12.6,0%,0%,,,
82,2,China,Chongqing,32,Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults,MedRxiv,Liao et al.,10.1101/2020.03.10.20032136,English,adolescents/young adults,Holly,,1/25/2020,2/23/2020,29,Subgroup,Young Adults (25-35 yrs),Positive only,End-point and active,Survivors only,Both,Yes,ΝΑ,All,NA,30,,,,,,53.10%,93.70%,40.50%,53.10%,,,,,,,,,12.50%,32.30%,15.60%,,,,,,,,,,,,,73.30%,,,76.70%,6.70%,20%,33.30%,6.70%,20%,3.30%,0%,3.30%,13.30%,,,6.70%,6.30%,,90.60%,3.10%,4.8,3.9,6.7,137.5,,128.5,150.5,1,,,1.3,0.9,1.8,194.5,,152,248,8.3,6.1,13.5,3.2,20,19.3,,30,,0.3,,61.5,3.15,57.6,0.03,,,,,,,,,,100%,,,,,,,,,93.80%,,,,,,,,0%,0,0%,0%,,0,0,0,0,0,6.30%,0,0,0,100%,,75%,,,12.5,0%,0%,,,
83,,China,,64,"Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis",MedRxiv,,10.1101/2020.03.09.20033118,English,all medical staff,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,0,China,Wuhan,48,Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O,MedRxiv,Xu et al.,10.1101/2020.02.26.20028084,English,"home monitoring, could be good for milder cases",Holly,,1/6/2020,1/31/2020,25,Top-level,All,Positive only,End-point and active,Non-Survivors only,Both,Yes,Both,All,NA,,39.08,13.88,,,,27.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,58.30%,,,33.30%,2.10%,6.30%,,10.40%,12.50%,,8.30%,,4.20%,2.10%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,1,China,Wuhan,42,Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O,MedRxiv,Xu et al.,10.1101/2020.02.26.20028084,English,"home monitoring, could be good for milder cases",Holly,,1/6/2020,1/31/2020,25,Subgroup,Non-hospitalized,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,,36.93,11.57,,,,23.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,52.40%,,,31%,2.40%,7.10%,,11.90%,11.90%,,9.50%,,4.80%,2.40%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,0.00%,,,,
84,2,China,Wuhan,6,Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O,MedRxiv,Xu et al.,10.1101/2020.02.26.20028084,English,"home monitoring, could be good for milder cases",Holly,,1/6/2020,1/31/2020,25,Subgroup,Hospitalized,Positive only,End-point and active,Survivors only,Both,Yes,Both,Severe/Critical Only,NA,,54,18.61,,,,50%,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,50%,0%,0%,,0%,16.70%,,0%,,0%,0%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,16.70%,16.70%,,,,0%,0%,,,
85,0,China,Wuhan,104,"Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China",MedRxiv,Qiu et al.,10.1101/2020.03.04.20026005,English,include detailed outcomes,Holly,,1/22/2020,2/12/2020,21,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,43,7.54,,,,47.12%,89.42%,46%,,,6,,,6,,,,3.85%,1.92%,,14.42%,11.54%,6.73%,,0.96%,,,,,,,,63.46%,,,75.96%,14.42%,,37.50%,19.23%,31.73%,,1.92%,,,,,,,,15.38%,,5.04,4.13,7.06,137.74,16.64,,,1,,,0.97,0.71,1.47,197.1,66.25,,,10.9,7.55,16.65,,20,26,,117.5,,0.47,37.35,66.09,,71,0.04,,,,,,,,,20.19%,99.04%,,,,,,8.65%,13.46%,,,,,,,,,,,,,11.54%,,,,4.81%,,2.14%,1.92%,,,,100%,8.65%,38.46%,,10.45,,0.96%,2.44%,,,
85,1,China,Wuhan,48,"Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China",MedRxiv,Qiu et al.,10.1101/2020.03.04.20026005,English,include detailed outcomes,Holly,,1/22/2020,2/12/2020,21,Subgroup,Imported,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,,40,10.67,,,,45.83%,,100%,,,5.5,,,6,,,,2.08%,2.08%,,12.50%,14.58%,2.08%,,0%,,,,,,,,75%,,,75%,18.75%,,29.17%,27.08%,33.33%,,0%,,,,,,,,16.67%,,4.99,4.16,5.94,138.52,14.82,,,1,,,0.85,0.66,1.09,198.27,69.81,,,11.04,7.6,19.62,,19.75,25.65,,113.5,,0.45,37.43,64.17,,71.5,0.03,,,,,,,,,22.92%,100%,,,,,,10.42%,20.83%,,,,,,,,,,,,,10.42%,,,,6.25%,,0%,0%,,,,100%,6.25%,52.08%,,11.16,,0%,0%,,,
85,2,China,Wuhan,56,"Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China",MedRxiv,Qiu et al.,10.1101/2020.03.04.20026005,English,include detailed outcomes,Holly,,1/22/2020,2/12/2020,21,Subgroup,Indigenous,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,44,19.76,,,,48.21%,,0%,,,6,,,6,,,,5.36%,1.79%,,16.07%,8.93%,10.71%,,1.79%,,,,,,,,53.57%,,,76.79%,10.71%,,44.64%,12.50%,30.36%,,3.57%,,,,,,,,14.28%,,5.14,4.09,7.5,14.82,18.24,,,1,,,1.08,0.76,1.64,196.04,63.52,,,7.26,7.26,14.01,,20.5,26.5,,119.5,,0.51,37.29,67.81,,69.5,0.04,,,,,,,,,17.86%,98.21%,,,,,,7.14%,7.14%,,,,,,,,,,,,,12.50%,,,,3.57%,,5.36%,3.57%,,,,100%,10.71%,26.79%,,9.27,,1.79%,6.26%,,,
86,0,Scotland,,1,The index case of SARS-CoV-2 in Scotland: a case report,Journal of Infection,Hill et. al.,https://doi.org/10.1016/j.jinf.2020.03.022,English,"Only one patient, but very detailed",Ryan,,1/3/2020,9/3/2020,7,Top-level,All,Positive only,End-point only,Both,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,51,51,,51,51,0%,100%,100%,0%,100%,7,7,7,7,3,3,3,3,0%,,,100%,0%,0%,,0%,0%,0%,0%,0%,,,,100%,,,100%,0%,0%,100%,100%,100%,,0%,0%,0%,100%,0%,,0%,100%,0%,0%,4.9,4.9,4.9,,,,,0,,,1.6,1.6,1.6,239,,239,239,,,,2.5,,,,4,,,,,,,,,,0%,0%,,,,,0%,0%,0%,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,100%,,8,8,0%,0%,,,
87,0,UK,England,2,Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission,Journal of Infection,Lillie et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30102-X/fulltext,English,Both patients reported seperately,Ryan,,1/23/2020,2/6/2020,14,Top-level,All,Positive only,End-point only,Both,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,36.5,36.5,,23,50,,50%,100%,,50%,4,4,4,4,4,4,3,5,,,,0%,0%,0%,,0%,0%,0%,0%,0%,,,,50%,37.3,37.3,50%,0%,0%,0%,50%,0%,0%,0%,0%,0%,50%,0%,,0%,100%,0%,0%,6.95,3.4,10.5,,,,,0,,,0.85,0.6,1.1,,,,,,,,5.535,,,,27.5,,,,,,,,,,50%,100%,,,,,100%,0%,0%,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,50%,0%,0%,0%,100%,0%,100%,,6.5,8.5,0.00%,0.00%,,,
87,1,UK,England,1,Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission,Journal of Infection,Lillie et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30102-X/fulltext,English,Patient 1,Ryan,,1/23/2020,2/6/2020,14,Subgroup,Patient 1,Positive only,End-point only,Both,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,50,50,,50,50,,0%,100%,,0%,4,4,4,4,5,5,5,5,,,,0%,0%,0%,,0%,0%,0%,0%,0%,,,,100%,37.6,37.6,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,0%,100%,0%,0%,3.4,3.4,3.4,,,,,0,,,0.6,0.6,0.6,,,,,,,,2.4,,,,15,,,,,,,,,,100%,100%,,,,,100%,0%,0%,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,100%,,4,7,0%,0%,,,
87,2,UK,England,1,Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission,Journal of Infection,Lillie et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30102-X/fulltext,English,Patient 2,Ryan,,1/23/2020,2/6/2020,14,Subgroup,Patient 2,Positive only,End-point only,Both,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,23,23,,23,23,,100%,100%,,100%,4,4,4,4,3,3,3,3,,,,0%,0%,0%,,0%,0%,0%,0%,0%,,,,0%,37,37,0%,0%,0%,0%,100%,0%,0%,0%,0%,0%,100%,0%,,0%,100%,0%,0%,10.5,10.5,10.5,,,,,0,,,1.1,1.1,1.1,,,,,,,,8.67,,,,40,,,,,,,,,,0%,100%,,,,,100%,0%,0%,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,100%,0%,0%,0%,100%,0%,100%,,9,10,0.00%,0.00%,,,
88,,USA,Illinois,1,First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.,The Lancet,Ghinai et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30607-3/fulltext,English,Lab test results reported in body of paper (not in tables),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
89,0,South Korea,Nationwide,28,Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea,Osong Public Health and Research Perspectives,Osong Public Health Dept,https://ophrp.org/journal/view.php?doi=10.24171/j.phrp.2020.11.1.03,English,"Published here: https://www.e-epih.org/upload/pdf/epih-42-e2020007.pdf, might be different data in published version",Holly,,1/20/2020,2/14/2020,25,Top-level,All,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,42.6,,,,,53.60%,,57%,36%,4.1,,,,,,,,,,35.70%,,,,,,3.60%,,,,,,,32.10%,,,17.90%,,,17.90%,14.30%,,,,,,32.10%,17.90%,,11%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,25%,,12.7,,,,,,
90,,Australia,Nationwide,295,"COVID-19, Australia: Epidemiology Report 7 (Reporting week ending 19:00 AEDT 14 March 2020).",COVID-19 National Surveillance Team,COVID-19 National Surveillance Team,https://www1.health.gov.au/internet/main/publishing.nsf/Content/1D03BCB527F40C8BCA258503000302EB/$File/covid_19_australia_epidemiology_report_7_reporting_week_ending_19_00_aedt_14_march_2020.pdf,English,"No lab data, but contains symptoms and hospitalization/fatality percentages; also look at previous 6 reports and split data into 7 rows (as discussed on 6pm friday call)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
91,,China,Zhejiang,651,"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms",Gut,Jin et. al.,http://dx.doi.org/10.1136/,English,,Ryan,,1/27/2020,2/8/2020,12,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,45.20935484,45.20935484,14.42044547,30.78890937,59.62980031,,50.84%,99.39%,59.14%,40.24%,,,,,,,,,6.32%,,27.35%,15.36%,7.38%,0.77%,,0.15%,0.92%,,0.92%,0.61%,,,,83.72%,,,66.82%,4.15%,,34.87%,,18.28%,,44.32%,44.32%,,,,,,9.83%,,,4.7171,3.76,5.95,137.72,,127.89,150.81,1,40.37,66,1.17,0.88,1.57,177.68,,145.43,217.77,9.65,7.02,13.18,2.93,21.90,24.96,,8.79,,,,,,,,,,,,,,,,42.55%,83.87%,83.87%,,,,,,,,,,2.61%,0%,11.37%,0%,,,0.30%,2.61%,2.61%,2.61%,,0%,0.30%,9.83%,,,,,,,100%,2.61%,,,,,0.15%,,,,
91,,China,Zhejiang,74,"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms",Gut,Jin et. al.,http://dx.doi.org/10.1136/,English,With GI Symptoms,Ryan,,1/27/2020,2/8/2020,12,Subgroup,GI Symptoms,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,46.14,46.14,14.19,31.95,60.33,,50%,94.59%,51.35%,43.24%,,,,,,,,,4.23%,,33.78%,16.22%,9.46%,1.35%,,0%,0%,,0%,0%,,,,85.14%,,,71.62%,10.81%,,39.19%,,31.08%,,0%,0%,,,,,,22.97%,,,4.85,3.8,6.34,135.5,,127,149.3,1,39.4,66,0.97,0.73,1.3,183,,141,216,10,7.15,13.8,3.14,25,29.35,,15.69,,,,,,,,,,,,,,,,41.89%,89.19%,89.19%,,,,,,,,,,6.76%,0%,14.86%,0%,,,1.35%,6.76%,6.76%,6.76%,,0%,1.35%,17.57%,,,,,,,100%,6.76%,,,,,0.15%,,,,
91,,China,Zhejiang,577,"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms",Gut,Jin et. al.,http://dx.doi.org/10.1136/,English,Without GI Symptoms,Ryan,,1/27/2020,2/8/2020,12,Subgroup,No GI Symptoms,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,45.09,45.09,14.45,30.64,59.54,,50.95%,100.00%,60.14%,39.86%,,,,,,,,,6.59%,,26.52%,15.25%,7.11%,0.69%,,0.17%,1.04%,,1.04%,0.69%,,,,83.54%,,,66.20%,3.30%,,34.32%,,16.64%,,50%,50%,,,,,,8.14%,,,4.7,3.76,5.9,138,,128,151,1,40.5,66,1.2,0.9,1.6,177,,146,218,9.6,7,13.1,2.9,21.5,24.4,,7.9,,,,,,,,,,,,,,,,42.63%,83.19%,83.19%,,,,,,,,,,2.08%,0%,10.92%,0%,,,0.17%,2.08%,2.08%,2.08%,,0%,0.17%,8.84%,,,,,,,100%,2.08%,,,,,0.15%,,,,
92,,China,Hunan,10,Short-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy,preprints.org,Zhou et. al.,doi: 10.20944/preprints202003.0065.v1,English,"Two versions of paper, make sure to download v2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
93,0,China,Shenzhen,5,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,"Contains patient level information, so please split into 5 rows",Ryan,,1/20/2020,3/25/2020,65,Top-level,All,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,65,59,29.71880544,55,65,,60%,,,,6.6,7,3,7,2.6,2,2,3,0%,,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,100%,37.552,38.5,,,,,,,,,,,,,,,100%,0%,100%,,,,,,,,1,,,,,,,,,,,,,,,,,160.06,147.9,,,,,,,,,,100%,,,,,,100%,80%,20%,,,,,,,,,100%,20%,,,,,,100%,,100%,,,,,,20%,,,,,100%,100%,60%,,53,,0.00%,0.00%,,,
93,1,China,Shenzhen,1,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,"Contains patient level information, so please split into 5 rows",Ryan,,1/20/2020,3/25/2020,65,Subgroup,Patient 1,Positive only,Active only,Both,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,75,75,0,75,75,,100%,,,,1,1,1,1,2,2,2,2,0%,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,100%,38,38.6,,,,,,,,,,,,,,,100%,0%,100%,,,,,,,,1,,,,,,,,,,,,,,,,,163.4,70.5,,,,,,,,,,100%,,,,,,100%,100%,0%,,,,,,,,,100%,0%,,,,,,100%,,100%,,,,,,0%,,,,,100.00%,100%,0%,,,,0%,,,,
93,2,China,Shenzhen,1,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,"Contains patient level information, so please split into 5 rows",Ryan,,1/21/2020,3/26/2020,65,Subgroup,Patient 2,Positive only,Active only,Both,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,65,65,0,65,65,,100.00%,,,,7,7,7,7,4,4,4,4,0%,,100%,100%,0%,100%,,0%,0%,0%,0%,0%,,,,100.00%,37.28,39,,,,,,,,,,,,,,,100%,0%,100%,,,,,,,,1,,,,,,,,,,,,,,,,,242.8,438.2,,,,,,,,,,100%,,,,,,100%,100%,0%,,,,,,,,,100%,100%,,,,,,100%,,100%,,,,,,100%,,,,,100.00%,100%,0%,,,,0%,,,,
93,3,China,Shenzhen,1,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,"Contains patient level information, so please split into 5 rows",Ryan,,1/22/2020,3/27/2020,65,Subgroup,Patient 3,Positive only,End-point only,Both,Discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,55,55,0,55,55,,0.00%,,,,3,3,3,3,2,2,2,2,0%,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,100.00%,37.08,37.6,,,,,,,,,,,,,,,100%,0%,100%,,,,,,,,1,,,,,,,,,,,,,,,,,65,63.9,,,,,,,,,,100%,,,,,,100%,100%,0%,,,,,,,,,100%,0%,,,,,,100%,,100%,,,,,,0%,,,,,100.00%,100%,100%,,53,,0%,0%,,,
93,4,China,Shenzhen,1,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,"Contains patient level information, so please split into 5 rows",Ryan,,1/23/2020,3/28/2020,65,Subgroup,Patient 4,Positive only,End-point only,Both,Discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,35,35,0,35,35,,0.00%,,,,7,7,7,7,2,2,2,2,0%,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,100.00%,37.5,38.3,,,,,,,,,,,,,,,100%,0%,100%,,,,,,,,1,,,,,,,,,,,,,,,,,156,79.1,,,,,,,,,,100%,,,,,,100%,0%,100%,,,,,,,,,100%,0%,,,,,,100%,,100%,,,,,,0%,,,,,100.00%,100%,100%,,51,,0%,0%,,,
93,5,China,Shenzhen,1,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,"Contains patient level information, so please split into 5 rows",Ryan,,1/24/2020,3/29/2020,65,Subgroup,Patient 5,Positive only,End-point only,Both,Discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,65,65,0,65,65,,100.00%,,,,15,15,15,15,3,3,3,3,0%,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,100.00%,37.9,39,,,,,,,,,,,,,,,100%,0%,100%,,,,,,,,1,,,,,,,,,,,,,,,,,173.1,87.8,,,,,,,,,,100%,,,,,,100%,100%,0%,,,,,,,,,100%,0%,,,,,,100%,,100%,,,,,,0%,,,,,100.00%,100%,100%,,55,,0%,0%,,,
94,0,Netherlands,Nationwide,86,SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020,MedRxiv,Kluytmans et. al.,https://www.medrxiv.org/content/10.1101/2020.03.23.20041913v1,English,"also have stratified by observation period, but I don't think this falls into our current system",Holly,,2/27/2020,,,Top-level,All,Positive only,End-point and active,Survivors only,Both,No,Non-ICU only,All,NA,49,,,,,100%,17.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,53.50%,,,75.60%,38.40%,57%,,64%,,,18.60%,17.40%,17.40%,39.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.30%,,,,,8,0%,,,,
94,1,Netherlands,Nationwide,32,SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020,MedRxiv,Kluytmans et. al.,https://www.medrxiv.org/content/10.1101/2020.03.23.20041913v1,English,"also have stratified by observation period, but I don't think this falls into our current system",Holly,,2/27/2020,,,Top-level,All,Positive only,End-point and active,Survivors only,Both,No,Non-ICU only,All,NA,47,,,,,100%,18.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,62.50%,,,65.60%,18.80%,56.30%,,65.60%,,,15.60%,3.10%,3.10%,34.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,,5,0%,,,,
94,2,Netherlands,Nationwide,54,SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020,MedRxiv,Kluytmans et. al.,https://www.medrxiv.org/content/10.1101/2020.03.23.20041913v1,English,"also have stratified by observation period, but I don't think this falls into our current system",Holly,,2/27/2020,,,Top-level,All,Positive only,End-point and active,Survivors only,Both,No,Non-ICU only,All,NA,49,,,,,100%,16.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,48.10%,,,81.50%,42.60%,57.40%,,81.50%,,,20.40%,25.90%,25.90%,50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.70%,,,,,9,0.00%,,,,
95,0,China,Hangzhou,10,Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression,,Liu et. al.,https://doi.org/10.1016/j.ijid.2020.03.013,English,Contains patient level data,Agni,,1/22/2020,2/11/2020,20,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,All,Non-ventilation only,42,,,34,50,,50%,100%,60%,40%,,5,3,7,,,,,,,,10%,0%,10%,,,0%,,10%,,10%,,0%,70%,,,80%,0%,30%,40%,,,10%,0%,30%,,40%,,,,,10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50%,,100%,,,,,,50%,,90%,,,,30%,,,,,,20%,,,,,,,0%,0%,,,,100%,30%,70%,,13,,,,,,
96,0,China,Wuhan,183,Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.,J Thromb Haemost,Tang et. al.,https://www.ncbi.nlm.nih.gov/pubmed/32073213,English,coagulation feature of patients,Agni,,1/1/2020,2/3/2020,34,Top-level,All,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,,54.1,16.2,,,,53.55%,,,,,,,,,,,,,,41%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11.48%,,,,
96,1,China,Wuhan,183,Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.,J Thromb Haemost,Tang et. al.,https://www.ncbi.nlm.nih.gov/pubmed/32073213,English,coagulation feature of patients,Agni,,1/1/2020,2/3/2020,34,Subgroup,Survivors,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,NA,,52.4,15.6,,,,50.62%,,,,,,,,,,,,,,38.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,
96,2,China,Wuhan,183,Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.,J Thromb Haemost,Tang et. al.,https://www.ncbi.nlm.nih.gov/pubmed/32073213,English,coagulation feature of patients,Agni,,1/1/2020,2/3/2020,34,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,,64,20.7,,,,76.19%,,,,,,,,,,,,,,57.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,,,
97,0,United Kingdom,Nationwide,775,ICNARC report on COVID-19 in critical care,,,https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b,English,Can obtain multiple rows by netting outcomes on 27th against outcomes on previous day (e.g. see https://www.icnarc.org/About/Latest-News/2020/03/22/Report-On-196-Patients-Critically-Ill-With-Covid-19),Agni,,2/29/2020,3/26/2020,27,Top-level,All,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,61,60.2,13.6,51,71,,70.50%,,,,,,,,,,,,,,,,,0.10%,,1.20%,4.70%,,2.70%,37.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.70%,,,,,,,,,,,,,,,,,,,,,100%,100%,11%,4,,,10%,48%,,,
97,0,United Kingdom,Nationwide,5338,ICNARC report on COVID-19 in critical care,,,https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b,English,Patients with viral pneumonia for non-COVID-19,Agni,,2017,3/26/2020,757,Top-level,Patients with viral pneumonia for non-COVID-19,Positive and Negative/Unconfirmed,End-point only,Both,Both,Yes,ICU only,Severe/Critical Only,Both,60,58,17.5,48,71,,54.30%,,,,,,,,,,,,,,,,,1.30%,,5.20%,14.60%,,3.00%,30.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,43.20%,,,,,,,,,,,,,,,,,,,,,100%,100%,72.20%,6,,,20.56%,22.16%,,,
97,1,United Kingdom,Nationwide,86,ICNARC report on COVID-19 in critical care,,,https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b,English,COVID-19 - discharged alive from critical care,Agni,,2/29/2020,3/26/2020,27,Subgroup,COVID-19 - discharged alive from critical care,Positive only,End-point only,Survivors only,Discharged only,Yes,ICU only,Severe/Critical Only,Both,60,,,50,69,,59.30%,,,,,,,,,,,,,,8.14%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,38.37%,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,0%,,,,
97,2,United Kingdom,Nationwide,79,ICNARC report on COVID-19 in critical care,,,https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b,English,COVID-19 - died in critical care,Agni,,2/29/2020,3/26/2020,27,Subgroup,COVID-19 - died in critical care,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Both,70,,,65,80,,73.42%,,,,,,,,,,,,,,12.66%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,82.28%,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,100%,,,,
98,,China,Sichuan,81,"Critical Care for Patients with Severe Covid-19 in Sichuan Province, China——A Provincial Cohort Study",MedRxiv,Liao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20041277v2.full.pdf,English,Can split into subgroups,Agni,,1/16/2020,3/15/2020,59,Top-level,Total,Positive only,End-point only,Both,Both,Yes,ΝΑ,All,Both,50,,,39,65,,63%,76.50%,45.70%,,,,,,,,,,3.70%,,53.10%,18.50%,22.20%,6.20%,,13.60%,0%,,3.70%,42%,,,,48.20%,,,49.40%,30.90%,,,,37%,,,,,,,,,,,,6.2,4.5,7.8,,,,,,,,0.8,0.6,1.1,166,,136,217,11.7,6.9,18.4,5,,,,,,,,,,,,,,,,,,,6.20%,71.60%,,87.70%,,,,,,18.50%,63%,9.90%,16%,0%,0%,,6.20%,,,1.20%,21%,37.70%,,,,,,,,7.40%,,,,,,,,,,12%,,,,
98,,China,Sichuan,53,"Critical Care for Patients with Severe Covid-19 in Sichuan Province, China——A Provincial Cohort Study",MedRxiv,Liao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20041277v2.full.pdf,English,Can split into subgroups,Agni,,1/16/2020,3/15/2020,59,Subgroup,Rapid Recovery,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,Both,49,,,39,63,,64.10%,79.30%,49.10%,,,,,,,,,,1.90%,,43.40%,17%,15.10%,3.80%,,9.40%,0%,,1.90%,34%,,,,47.20%,,,54.70%,32.10%,,,,37.70%,,,,,,,,,65.43%,0%,0%,6.3,4.9,8.2,,,,,,,,0.8,0.6,1.1,178,,139,237,12.6,9,17.5,4.6,,,,,,,,,,,,,,,,,,,3.80%,73.60%,,88.70%,,,,,,18.90%,64.20%,9.40%,15.10%,0%,0%,,0%,,,0%,13.20%,37.70%,,,,,,,,5.70%,,,,,,,,,,0.00%,,,,
98,,China,Sichuan,10,"Critical Care for Patients with Severe Covid-19 in Sichuan Province, China——A Provincial Cohort Study",MedRxiv,Liao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20041277v2.full.pdf,English,Can split into subgroups,Agni,,1/16/2020,3/15/2020,59,Subgroup,No Recovery,Positive only,End-point only,Non-Survivors only,Non-discharged only,Yes,ΝΑ,Severe/Critical Only,Both,76,,,64,80,,40%,60%,30%,,,,,,,,,,10%,,100%,40%,30%,30%,,30%,0%,,20%,90%,,,,50%,,,30%,30%,,,,20%,,,,,,,,,0%,0%,12.35%,6.7,4.9,7.4,,,,,,,,0.4,0.3,1.1,124,,111,147,7.9,3.5,19.5,5.4,,,,,,,,,,,,,,,,,,,30%,80%,,60%,,,,,,20%,70%,0%,20%,0%,0%,,50%,,,10%,50%,40%,,,,,,,,30%,,,,,,,,,,100.00%,,,,
98,,China,Sichuan,18,"Critical Care for Patients with Severe Covid-19 in Sichuan Province, China——A Provincial Cohort Study",MedRxiv,Liao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20041277v2.full.pdf,English,Can split into subgroups,Agni,,1/16/2020,3/15/2020,59,Subgroup,Pronged Recovery,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Severe/Critical Only,Both,48,,,37,60,,72.20%,77.80%,44.40%,,,,,,,,,,5.60%,,55.60%,11.10%,38.90%,0%,,16.70%,0%,,0%,38.90%,,,,50%,,,61.10%,27.80%,,,,44.40%,,,,,,,,,0%,22.22%,0%,5.9,3.9,9.5,,,,,,,,0.8,0.6,1.1,169.5,,150,202,10.8,6.2,19.7,4.2,,,,,,,,,,,,,,,,,,,0%,61.10%,,100%,,,,,,16.70%,55.60%,16.70%,16.70%,0%,0%,,0%,,,0%,27.80%,33.30%,,,,,,,,0%,,,,,,,,,,0.00%,,,,
99,0,China,Shenzhen,391,"Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v3.full.pdf,English,Total,Agni,,1/14/2020,2/12/2020,27,Top-level,Total,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,49,,,,,,47.80%,96.93%,0%,22.25%,,,,,,,,,,,,,,,,,,,,,,,,84.40%,,,39.10%,3.10%,16.10%,,19.40%,13.60%,,0.80%,1%,,6.60%,5.60%,3.30%,6.40%,84.70%,9%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,57.54%,,,,0.77%,1.32%,,,
99,1,China,Shenzhen,87,"Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v3.full.pdf,English,Contact based,Agni,,1/14/2020,2/12/2020,27,Subgroup,Contact based,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,39,,,,,,27.60%,100%,0%,100%,,,,,3.2,,,,,,,,,,,,,,,,,,,71.30%,,,23%,8.30%,11.50%,,6.90%,8%,,1.10%,0%,,4.60%,2.30%,2.30%,19.50%,77.10%,3.40%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99,2,China,Shenzhen,292,"Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v3.full.pdf,English,Symptom based,Agni,,1/14/2020,2/12/2020,27,Subgroup,Symptom based,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,45,,,,,,55.10%,100%,0%,0%,,,,,5.5,,,,,,,,,,,,,,,,,,,88.40%,,,43.50%,3.80%,17.50%,,23.60%,15.40%,,0.70%,1%,,6.50%,6.80%,3.80%,2.70%,87.00%,10.30%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99,3,China,Shenzhen,12,"Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v3.full.pdf,English,Uknown,Agni,,1/14/2020,2/12/2020,27,Subgroup,Uknown,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,59,,,,,,16.70%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,83.30%,,,50%,0%,16.70%,,8.30%,8.30%,,0%,0%,,25%,0%,0%,0%,83.40%,16.70%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
100,0,China,Wuhan,120,Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection,MedRxiv,Yan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040832v1.full.pdf,English,,Ryan,,1/31/2020,3/9/2020,38,Top-level,All,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,All,Both,52,,,35,63,,45%,,,,,,,,,,,,10%,,,26.70%,8.30%,5.80%,,1.60%,5.80%,,0.80%,2.50%,,,,,,,,,,,,,,,,,,,,0%,25.87%,25.03%,0.84%,5.65,4.14,7.33,,,,,,,61,1.14,0.81,1.55,195,,144,269,,,,,,31,,,,,,,,,,,,24.30%,,27.70%,,,,85%,,65%,0%,,,,45%,0%,,17.50%,1.70%,0.80%,0%,0%,0%,,,,,,,,,,,,,,,,,100%,0%,100%,,21,23,0%,0%,,,
100,1,China,Wuhan,78,Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection,MedRxiv,Yan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040832v1.full.pdf,English,LPV/r group,Ryan,,1/31/2020,3/9/2020,38,Subgroup,LPV/r group,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,All,Both,50,,,34,61,,44.90%,,,,,,,,,,,,10.30%,,,24.40%,10.30%,6.40%,,1.30%,5.10%,,1.30%,2.60%,,,,,,,,,,,,,,,,,,,,0%,32.10%,32.10%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,32.60%,,26.90%,,,,93.60%,,100%,0%,,,,56.40%,0%,,21.80%,1.30%,1.30%,0%,0%,0%,,,,,,,,,,,,,,,,,100%,0%,100%,,23,22,0%,0%,,,
100,2,China,Wuhan,42,Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection,MedRxiv,Yan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040832v1.full.pdf,English,No LPV/r group,Ryan,,1/31/2020,3/9/2020,38,Subgroup,No LPV/r group,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,All,Both,57,,,36.5,66,,45.20%,,,,,,,,,,,,9.50%,,,31%,4.80%,4.80%,,2.40%,7.10%,,0%,2.40%,,,,,,,,,,,,,,,,,,,,0%,14.30%,11.90%,2.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.50%,,28.60%,,,,71.40%,,0%,0%,,,,23.80%,0%,,9.50%,2.40%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,100%,0%,100%,,18.5,28.5,0.00%,0.00%,,,
101,0,France,Marseille,80,Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study,MedRxiv,Gautret et. al.,https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf,English,,Ryan,,3/3/2020,3/21/2020,18,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,52.5,52.5,,42,62,,52.50%,,,,,,,,4.8,4.8,0,10.4,,,,16.30%,11.20%,7.50%,,10%,6.30%,,,7.50%,,,,15%,38.6,38.8,58.80%,,,,,,,,,,16.30%,,,5%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22.50%,100%,0%,0%,,,,,,,15%,,,,,,,,,,,,,,,,,,,,,,100%,3.80%,81.20%,,4,,1.20%,1.46%,,,
102,0,China,Wuhan,236,Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2.full.pdf,English,,Ryan,,2/20/2020,3/12/2020,21,Top-level,All,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,51.52542373,51.52542373,,,,,46.61%,,,,,,,,,,,,,,,27.96%,11.44%,,,,,,,24.57%,,,,52.96%,,,56.78%,5.51%,,,2.12%,28.39%,,15.68%,,,11.02%,,,0%,11.44%,11.44%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,23.99%,100%,0%,49.15%,,,,0%,0%,0%,0%,,,0%,6.35%,0%,,,,2.09%,2.09%,,,,,,,,,,,,100%,,2.11%,,,,0%,0%,,,
102,1,China,Wuhan,116,Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2.full.pdf,English,Favipiravir group,Ryan,,2/20/2020,3/12/2020,21,Subgroup,Favipiravir group,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,50,50,,,,,50.86%,,,,,,,,,,,,,,,31.03%,12.07%,,,,,,,18.96%,,,,55.17%,,,60.34%,7.76%,,,1.72%,34.48%,,18.97%,,,7.76%,,,0%,15.52%,15.52%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.33%,100%,0%,100%,,,,0%,0%,0%,0%,,,0%,4.30%,0%,,,,0.80%,0.80%,,,,,,,,,,,,100%,,0%,,,,0.00%,0.00%,,,
102,2,China,Wuhan,120,Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2.full.pdf,English,Arbidol group,Ryan,,2/20/2020,3/12/2020,21,Subgroup,Arbidol group,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,53,53,,,,,42.50%,,,,,,,,,,,,,,,25.00%,10.83%,,,,,,,30.00%,,,,50.83%,,,53.33%,3.33%,,,2.50%,22.50%,,12.50%,,,14.17%,,,0%,7.50%,7.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19.80%,100%,0%,0%,,,,0%,0%,0%,0%,,,0%,8.33%,0%,,,,3.33%,3.33%,,,,,,,,,,,,100.00%,,5%,,,,0%,0%,,,
103,0,USA,Washington,167,"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington",NEJM,McMichael et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2005412?articleTools=true,English,Less data than ideal but from US (which we lack data on) so recommend keeping,Ryan,,2/27/2020,3/18/2020,20,Top-level,All,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,72,72,,,,29.90%,32.90%,,,,,,,,,,,,,,,44.30%,22.80%,40.70%,,21.60%,9%,,25.70%,25.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,39.50%,,,,,,21.00%,53%,,,
103,1,USA,Washington,101,"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington",NEJM,McMichael et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2005412?articleTools=true,English,Residents,Ryan,,2/27/2020,3/18/2020,20,Subgroup,Residents,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,83,83,,,,0%,31.70%,,,,,,,,,,,,,,,67.30%,31.70%,60.40%,,31.70%,14.90%,,40.60%,36.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,54.50%,,,,,,33.70%,62%,,,
103,2,USA,Washington,50,"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington",NEJM,McMichael et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2005412?articleTools=true,English,Healthcare Personnel,Ryan,,2/27/2020,3/18/2020,20,Subgroup,Healthcare Personel,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,43.5,43.5,,,,100%,24%,,,,,,,,,,,,,,,8%,10%,8%,,4%,0%,,0%,6%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6%,,,,,,0.00%,0%,,,
103,3,USA,Washington,16,"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington",NEJM,McMichael et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2005412?articleTools=true,English,Visitors,Ryan,,2/27/2020,3/18/2020,20,Subgroup,Visitors,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,62.5,62.5,,,,0%,68.80%,,,,,,,,,,,,,,,12.50%,6.20%,18.80%,,12.50%,0%,,12.50%,18.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50%,,,,,,6.20%,12%,,,
104,0,China,Wuhan,52,"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study",The Lancet Respiratory Medicine,Yang et. al.,https://www.sciencedirect.com/science/article/pii/S2213260020300795,English,Can split by survivors/non-survivors,Kim,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
105,0,China,Chongqing,80,Chest CT Findings in Patients with Corona Virus Disease 2019 and its Relationship with Clinical Features,Investigative Radiology,Wu et. al.,https://doi.org/10.1097/RLI.0000000000000670,English,,EXCLUDE,,1/1/2020,2/1/2020,31,Top-level,All,Positive only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
106,0,China,Wuhan,155,"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China",Clinical Infectious Diseases,Mo et. al.,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa270/5805508,English,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
107,0,China,Wuhan,83,"Acute gastrointestinal injury in critically ill patients with coronavirus disease 2019 in Wuhan, China",MedRxiv,Sun et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20043570v1.full.pdf,English,,Kim,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
108,0,China,Wuhan,1,A special case of COVID-19 with long duration of viral shedding for 49 days,MedRxiv,Tan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040071v1.full.pdf,English,Can split two patients into patient level data,Kim,,1/14/2020,3/19/2020,,Subgroup,patient 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,1,A special case of COVID-19 with long duration of viral shedding for 49 days,MedRxiv,Tan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040071v1.full.pdf,English,,Kim,,,,,Subgroup,patient 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
109,0,China,Wuhan,377,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,"No top-level stats, extrapolated them",Arthur,,1/1/2020,2/28/2020,58,Top-level,Extrapolated top-level stats,Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,53.71,,38.23,69.20,,45.09%,,,,7.69,,3.14,12.24,,,,,,,,35.23%,22.30%,5.57%,,,,,,,,,,,,,,,,,,,,,,,,,,,68.97%,31.03%,,5.05,3.95,6.71,,,,,,,,1.01,0.77,1.35,,,,,,,,3.59,20.32,23.00,,2.32,,1.37,38.55,64.68,4.37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
109,1,China,Wuhan,171,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,,Arthur,,1/1/2020,2/28/2020,58,Subgroup,Non-severe train,Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,49.05,,32.44,65.66,,38.60%,,,,7.61,,2.89,12.33,,,,,,,,23.29%,17%,4.09%,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,,5.13,3.78,6.42,,,,,,,,1.12,0.89,1.54,,,,,,,,3.25,19.6,20,,0.85,,0.45,39.74,59.3,3.78,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
109,2,China,Wuhan,79,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,,Arthur,,1/1/2020,2/28/2020,58,Subgroup,Severe train,Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,65.23,,50.23,80.23,,56.96%,,,,7.15,,3.32,10.98,,,,,,,,62.03%,36.71%,6.33%,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,,5.51,4,7.3,,,,,,,,0.66,0.46,0.95,,,,,,,,4.24,23.7,31.6,,6.1,,3.26,35.84,72.1,5.58,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
109,3,China,Wuhan,89,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,,Arthur,,1/1/2020,2/28/2020,58,Subgroup,Non-severe test,Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,47,,31.71,62.29,,40.45%,,,,8.24,,3.45,13.03,,,,,,,,25.84%,14.61%,3.37%,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,,5.2,3.99,6.3,,,,,,,,1.22,0.91,1.51,,,,,,,,3.4,17.3,19,,0.74,,0.56,40.07,64.8,3.92,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
109,4,China,Wuhan,38,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,,Arthur,,1/1/2020,2/28/2020,58,Subgroup,Severe test,Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,66.47,,54.57,78.37,,60.53%,,,,7.89,,3.14,12.64,,,,,,,,55.26%,34.21%,15.79%,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,,3.43,4.47,7.76,,,,,,,,0.72,0.5,0.97,,,,,,,,4.24,23.6,27.95,,4.77,,3.45,35.22,73.2,5.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
110,0,China,Wuhan,323,"Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China",,Hu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20037721v1.full.pdf,English,Can split by severity; clinical outcome,Kim,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
111,0,China,Wuhan,187,Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19),JAMA Cardiology,Guo et. al.,https://jamanetwork.com/journals/jamacardiology/article-abstract/2763845,English,General,Agni,,1/23/2020,2/23/2020,29,Top-level,General,Positive only,End-point only,Both,Both,Yes,ΝΑ,All,Both,,58.5,14.66,,,,48.70%,,,,,,,,,,,,9.60%,,,32.60%,15%,11.20%,,2.10%,7%,,3.20%,,,,,,,,,,,,,,,,,,,,,,,,,4.9,3.8,7.4,,,,,,,,0.8,0.6,1.1,,,,,,,,3.7,,,,4.04,,,,69,,,0.08,,,,,,,,,97.90%,88.80%,,,,,,,11.20%,,,24.10%,,,56.70%,,,,,,,24.60%,,5.90%,,15.40%,34.10%,,14.60%,,,,100%,,77%,,16.63,,23%,23%,,,
111,1,China,Wuhan,135,Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19),JAMA Cardiology,Guo et. al.,https://jamanetwork.com/journals/jamacardiology/article-abstract/2763845,English,TnT level normal,Agni,,1/23/2020,2/23/2020,29,Subgroup,TnT level normal,Positive only,End-point only,Both,Both,Yes,ΝΑ,All,Both,,53.53,13.22,,,,42.20%,,,,,,,,,,,,8.10%,,,20.70%,8.90%,3.00%,,0%,5.20%,,0.70%,,,,,,,,,,,,,,,,,,,,,,,,,4.6,3.7,6.1,,,,,,,,0.84,0.63,1.13,,,,,,,,3.1,,,,3.13,,,,63,,,0.05,,,,,,,,,97%,88.90%,,,,,,,10.40%,,,10.40%,,,51.10%,,,,,,,11.90%,,1.50%,,16.50%,20%,,4.70%,,,,100%,,91.10%,,17.27,,8.90%,8.90%,,,
111,2,China,Wuhan,52,Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19),JAMA Cardiology,Guo et. al.,https://jamanetwork.com/journals/jamacardiology/article-abstract/2763845,English,TnT level elevated,Agni,,1/23/2020,2/23/2020,29,Subgroup,TnT level elevated,Positive only,End-point only,Both,Both,Yes,ΝΑ,All,Both,,71.4,9.43,,,,65.40%,,,,,,,,,,,,13.50%,,,63.50%,30.80%,32.70%,,7.70%,11.50%,,9.60%,,,,,,,,,,,,,,,,,,,,,,,,,7.4,4.9,11.6,,,,,,,,0.69,0.34,1.01,,,,,,,,6,,,,8.55,,,,79,,,0.21,,,,,,,,,100%,88.50%,,,,,,,13.50%,,,59.60%,,,71.20%,,,,,,,57.70%,,17.30%,,13.20%,65.80%,,36.80%,,,,100%,,40.40%,,14.94,,59.60%,59.60%,,,
112,0,China,Wuhan,416,"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China",JAMA Cardiology,Shi et. al.,https://jamanetwork.com/journals/jamacardiology/fullarticle/2763524,English,Can split on cardiac injury,Kim,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
113,0,China,Wuhan,173,Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019,MedRxiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.02.20030189v1.full.pdf,English,Can split on condition type,Arthur,,1/11/2020,2/9/2020,29,Top-level,,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,48,,,35,61,,49%,,72.80%,,,,,,,,,,,,24%,12%,6.40%,1.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,81.50%,,18.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,36%,,,,1.20%,3.23%,,,
113,1,China,Wuhan,141,Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019,MedRxiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.02.20030189v1.full.pdf,English,Can split on condition type,Arthur,,1/11/2020,2/9/2020,29,Subgroup,Non-critical,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,Non-ventilation only,41,,,33,56,,45%,,71.40%,,,,,,,,,,,,18%,7.80%,4.30%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,,,,,,,,,,,,,,,,,,,,,38%,,,,0%,0%,,,
113,2,China,Wuhan,32,Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019,MedRxiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.02.20030189v1.full.pdf,English,Can split on condition type,Arthur,,1/11/2020,2/9/2020,29,Subgroup,Critical,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,Ventilation only,64,,,58,66,,66%,,78.10%,,,,,,,,,,,,47%,28%,16%,9.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,25%,,,,6.30%,20.13%,,,
114,0,China,Guangzhou,10,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Has patient level data,Arthur,,1/14/2020,2/20/2020,37,Top-level,,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,6.625,7.543,,2.1675,13.3975,0%,60.00%,100%,70.00%,30.00%,,,,,,,,,0%,0%,,,,,,,,,,,,,,70.00%,,38.5,50.00%,,,,,,,30.00%,,,50.00%,,,,,,,7.8,4.7,8.8,124,18.77,115,137,100.00%,,,1.75,1.35,4.73,286,,229,301,3.8,3.3,5.9,2.76,17,23,,1.14,,0.32,45.1,29,3.61,103,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,40%,,20,,0.00%,0.00%,,,
114,1,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 1,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,6.17,6.17,,,,0%,100%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,100.00%,,39.1,100.00%,,,,,,,100.00%,,,0.00%,,,,,,,12,,,115,,,,100.00%,,,1.35,,,229,,,,3.5,,,9.24,20,33,,2.43,,0.41,44.6,29,3.5,117,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,0.00%,,28,,0.00%,,,,
114,2,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 2,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,12.58,12.58,,,,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,100.00%,,39.2,0.00%,,,,,,,0.00%,,,100.00%,,,,,,,4.6,,,124,,,,100.00%,,,0.89,,,173,,,,5.9,,,3.21,6,17,,0.31,,0.28,47.9,49,2.4,64,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,100.00%,,10,,0.00%,0.00%,,,
114,3,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 3,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,7.08,7.08,,,,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,100.00%,,38.4,100.00%,,,,,,,100.00%,,,100.00%,,,,,,,7.9,,,116,,,,100.00%,,,0.65,,,301,,,,2.6,,,6.48,11,23,,16.13,,0.33,39.8,29,2.5,71,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,0.00%,,23,,0.00%,,,,
114,4,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 4,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,13.75,13.75,,,,0%,100%,100%,0.00%,100.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,0.00%,,,0.00%,,,,,,,0.00%,,,0.00%,,,,,,,4.7,,,145,,,,100.00%,,,2.17,,,141,,,,8.7,,,1.97,11,16,,0.3,,0.26,44.5,55,3.61,64,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,100.00%,,9,,0.00%,0.00%,,,
114,5,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 5,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,1.17,1.17,,,,0%,100%,100%,0.00%,100.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,100.00%,,37.8,0.00%,,,,,,,0.00%,,,0.00%,,,,,,,7.8,,,115,,,,100.00%,,,6.19,,,363,,,,2.8,,,1.08,31,62,,1.14,,0.32,45.1,22,3.2,278,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,0.00%,,23,,0.00%,,,,
114,6,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 6,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,3.42,3.42,,,,0%,100%,100%,0.00%,100.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,0.00%,,,0.00%,,,,,,,0.00%,,,100.00%,,,,,,,8.8,,,135,,,,100.00%,,,4.73,,,286,,,,3.3,,,2.76,21,36,,0.3,,0.24,46,29,4.6,75,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,0.00%,,21,,0.00%,,,,
114,7,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 7,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,15.67,15.67,,,,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,100.00%,,38.5,0.00%,,,,,,,0.00%,,,0.00%,,,,,,,4,,,137,,,,100.00%,,,1.66,,,291,,,,3.8,,,1.99,14,20,,11.86,,0.23,48.3,50,4.8,113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,100.00%,,8,,0.00%,0.00%,,,
114,8,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 8,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,13.67,13.67,,,,0%,100%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,100.00%,,38.5,100.00%,,,,,,,0.00%,,,100.00%,,,,,,,7.8,,,163,,,,100.00%,,,1.75,,,240,,,,6.6,,,51,17,22,,22.05,,0.5,48.2,59,5.9,103,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,0.00%,,19,,0.00%,,,,
114,9,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 9,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,0.17,0.17,,,,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,0.00%,,,100.00%,,,,,,,0.00%,,,100.00%,,,,,,,10.8,,,102,,,,100.00%,,,9.05,,,342,,,,4.9,,,1.23,172,127,,1.04,,0.84,39.5,15,4.6,112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,100.00%,,,,0.00%,0.00%,,,
114,10,China,Guangzhou,1,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,,Arthur,,1/14/2020,2/20/2020,37,Subgroup,Patient 10,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,1.75,1.75,,,,0%,100%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,,100.00%,,38,100.00%,,,,,,,100.00%,,,0.00%,,,,,,,,,,,,,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,,0.00%,,,,0.00%,,,,
115,1,China,Hainan,18,Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients,Journal of Infection,Liu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30116-X/pdf,English,Elderly,Arthur,,1/1/2020,2/15/2020,45,Subgroup,Elderly,Positive only,End-point only,Both,Both,Yes,Both,All,Both,68,,,65.25,69.75,,66.67%,,,,,,,,,,,,44.44%,,,27.78%,16.67%,11.11%,,,,,0%,,,,,77.78%,,,33.33%,11.11%,,33.33%,,11.11%,,,16.67%,,5.56%,,,,,,,5.38,4.33,6.13,107.35,,92.13,120.35,,,,,,,207,,159,287,,,,,,,,22.74,,,33,106.44,,,,,,,,,,,,66.67%,,83.33%,,,,,,22.22%,,94.44%,5.56%,22.22%,5.56%,,11.11%,,,,,,22.22%,,16.67%,5.56%,,,,38.89%,22.22%,,,100%,,94.44%,,,,5.56%,5.56%,,,
115,2,China,Hainan,38,Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients,Journal of Infection,Liu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30116-X/pdf,English,Young,Arthur,,1/1/2020,2/15/2020,45,Subgroup,Young,Positive only,End-point only,Both,Both,Yes,Both,All,Both,47,,,35.75,51.25,,50.00%,,,,,,,,,,,,36.84%,,,13.16%,2.63%,0%,,,,,2.63%,,,,,78.95%,,,39.47%,5.26%,,39.47%,,7.89%,,,18.42%,,5.26%,,,,,,,4.48,3.74,5.88,125.21,,114.23,140.15,,,,,,,215,,180,287,,,,,,,,6.49,,,39,88.71,,,,,,,,,,,,73.68%,,86.84%,,,,,,13.16%,,97.37%,5.26%,7.89%,2.63%,,7.89%,,,,,,5.26%,,10.53%,5.26%,,,,7.89%,13.16%,,,100%,,94.74%,,,,5.26%,5.26%,,,
116,0,China,Hunan,32,Comparisons of nucleic acid conversion time of SARS-CoV-2 ofdifferent samples in ICU and non-ICU patients,Journal of Infection,Fang et. al.,https://doi.org/10.1016/j.jinf.2020.03.013,English,,Arthur,,1/1/2020,2/29/2020,59,Top-level,,Positive only,End-point and active,Both,Both,No,Both,All,NA,41,,,,,,50.00%,87.50%,43.80%,37.50%,5,,,,,,,,,,,15.60%,12.50%,3.10%,,,,,,6.30%,,,,53.10%,,,75%,31.20%,18.80%,,18.80%,15.60%,,9.40%,,,21.90%,,,12.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,25%,,,,,,,,,
117,0,China,Yichang,197,"Clinical features and outcomes of 197 adult discharged patients with COIVD-19 in Yichang, Hubei",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.26.20041426v1.full.pdf,English,Hard to read due to poor English,Arthur,,1/17/2020,2/26/2020,40,Top-level,,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,55.94,,37.11,74.77,,50.30%,,20.80%,75.50%,6.14,,,,,,,,,,,,9.10%,24.40%,,,,,1.50%,,,,,77.66%,,,45.20%,5.10%,,,4.60%,14.70%,,,,,5.60%,,,,,,,5.79,2.66,8.92,,,,,,,,1.13,0.39,1.87,165.35,,97.38,233.32,16.31,2.45,30.17,4.18,38.4,38.84,,54.97,,2309.36,,,,133.67,0.46,,,,,,,,,76.60%,90.90%,,,,,,,26.90%,,76.60%,15.30%,8.10%,,38.10%,,,,,,,13.20%,,7.10%,6.10%,4.10%,,,8.10%,,,,,29.40%,,,15.08,,14.20%,,,,
118,0,China,Wuhan,80,The potential role of IL-6 in monitoring severe case of coronavirus disease 2019,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf,English,Can split by severity,Arthur,,1/21/2020,2/16/2020,26,Top-level,,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,53,,,,,,42.50%,,,,,,,,,,,,10%,,35%,17.50%,13.75%,7.50%,,,8.75%,,0%,,,,,57.50%,,,66.25%,,,18.75%,15%,45%,,18.75%,8.75%,,10%,16.25%,,,,,,,,,127.1,15.32,,,,,,1.11,0.6,1.62,,,,,,,,,,,,,,,,,,,,,,,75%,33.75%,33.75%,,,91.25%,,6.25%,,,,,,,48.75%,13.75%,7.50%,2.50%,0%,,0%,,,,,,8.75%,,,1.25%,,0%,,0%,,,,100%,3.75%,58.75%,,,,0%,0%,,,
118,1,China,Wuhan,11,The potential role of IL-6 in monitoring severe case of coronavirus disease 2019,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf,English,Can split by severity,Arthur,,1/21/2020,2/16/2020,26,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,Yes,Both,Mild only,Both,31,,,,,,9.09%,,,,,,,,,,,,0%,,27.27%,0%,0%,0%,,,27.27%,,0%,,,,,18.18%,,,81.82%,,,9.09%,0%,9.09%,,36.36%,18.18%,,36.36%,0%,,,,,,,,,127.8,16.13,,,,,,1.61,1.22,2,,,,,,,,,,,,,,,,,,,,,,,9.09%,9.09%,9.09%,,,100%,,0%,,,,,,,9.09%,0%,0%,0%,0%,,0%,,,,,,0%,,,0%,,0%,,0%,,,,100.00%,0%,90.91%,,,,0%,0%,,,
118,2,China,Wuhan,69,The potential role of IL-6 in monitoring severe case of coronavirus disease 2019,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf,English,Can split by severity,Arthur,,1/21/2020,2/16/2020,26,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,56,,,,,,47.83%,,,,,,,,,,,,11.59%,,36.23%,20.29%,15.94%,8.70%,,,5.80%,,0%,,,,,63.77%,,,63.77%,,,20.29%,17.39%,50.72%,,15.94%,7.25%,,5.80%,18.84%,,,,,,,,,122.7,7.82,,,,,,1.03,0.55,1.51,,,,,,,,,,,,,,,,,,,,,,,85.51%,37.68%,37.68%,,,89.86%,,7.25%,,,,,,,55.07%,15.94%,8.70%,2.90%,0%,,0%,,,,,,10.14%,,,1.45%,,0%,,0%,,,,100%,4.35%,53.62%,,,,0%,0%,,,
119,0,China,Northeast Region,55,"Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study",MedRxiv,Fan et al,https://www.medrxiv.org/content/10.1101/2020.03.28.20045955v1.full.pdf,English,"all recovered, some typos in manuscript",Holly,,1/20/2020,3/15/2020,55,Top-level,All,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,All,NA,,46.8,,,,,54.50%,,50.91%,32.72%,,,,,,,,,,,,14.55%,14.55%,5.45%,,,,,,,,,,46.18%,,,49.09%,14.55%,3.64%,,12.73%,14.55%,,10.91%,7.27%,,12.73%,,,,,,,6.13,,,,,,,1,,,1.61,,,,,,,19.47,,,,40.65,,,203.1,,0.62,,54.25,,,0.08,,,,,,,,,52.73%,96.36%,16.36%,,36.36%,32.73%,,12.73%,,,,,,,,,34.50%,16.40%,,,,3.64%,27.27%,,,30.91%,,,,,,,100%,,100%,,,,0%,0%,,,
119,1,China,Northeast Region,47,"Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study",MedRxiv,Fan et al,https://www.medrxiv.org/content/10.1101/2020.03.28.20045955v1.full.pdf,English,"all recovered, some typos in manuscript",Holly,,1/20/2020,3/15/2020,55,Subgroup,Mild,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,NA,,46.4,,,,,51.10%,,46.81%,34.04%,,,,,,,,,,,,17.02%,14.89%,4.26%,,,,,,,,,,51.06%,,,51.06%,10.64%,4.26%,,10.64%,17.02%,,8.51%,4.26%,,10.64%,,,,,,,5.78,,,,,,,1,,,1.76,,,,,,,18.98,,,,37.85,,,157.3,,0.48,,54.13,,,0.07,,,,,,,,,46.67%,95.74%,10.64%,,36.17%,36.17%,,6.38%,,,,,,,,,36.17%,12.76%,,,,0%,14.89%,,,23.40%,,,,,,,100%,,100%,,,,0%,0%,,,
119,2,China,Northeast Region,8,"Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study",MedRxiv,Fan et al,https://www.medrxiv.org/content/10.1101/2020.03.28.20045955v1.full.pdf,English,"all recovered, some typos in manuscript",Holly,,1/20/2020,3/15/2020,55,Subgroup,Severe,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Severe/Critical Only,NA,,46.12,,,,,75%,,75%,25%,,,,,,,,,,,,0%,12.50%,12.50%,,,,,,,,,,100%,,,37.50%,37.50%,0%,,25%,0%,,25%,25%,,25%,,,,,,,8.18,,,,,,,1,,,0.78,,,,,,,22.38,,,,57.13,,,472.1,,1.44,,55,,,0.11,,,,,,,,,100.00%,100%,50%,,37.50%,12.50%,,50%,,,,,,,,,25%,37.50%,,,,25%,100%,,,75%,,,,,,,10%,,100%,,,,0.00%,0.00%,,,
120,0,USA,Washington,24,Covid-19 in Critically Ill Patients in the Seattle Region — Case Series,NEJM,Bhatraju et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2004500?articleTools=true,English,Patient level info on length of stay and outcome; please enter each one of these entries as one row,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
121,0,China,,206,"Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes",,Han et. al.,https://journals.lww.com/ajg/Documents/COVID19_Han_et_al_AJG_Preproof.pdf,English,Can split by digestive symptoms,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
122,1,USA,Washington,53,"Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e1.htm,English,Contains both negative/positive cases,Holly,,2/28/2020,3/20/2020,21,Subgroup,Negative Cases,Negative only,Active only,Both,Both,No,ΝΑ,All,NA,,75.1,,,,,39.60%,,,,,,,,,,,,13.20%,,100%,,37.70%,,67.90%,30.20%,,,34%,,,,,5.70%,,,11.30%,0%,0%,,0%,,1.90%,5.70%,0%,,3.80%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
122,2,USA,Washington,23,"Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e1.htm,English,Contains both negative/positive cases,Holly,,2/28/2020,3/20/2020,21,Subgroup,Positive Cases,Positive only,Active only,Both,Both,No,ΝΑ,All,NA,,80.7,,,,,30.40%,,,,,,,,,,,,4.40%,,95.70%,,39.10%,,87%,43.50%,,,39.10%,,,,,4.30%,,,30.40%,4.40%,0%,,0%,,0%,4.40%,13%,,8.70%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,